Page last updated: 2024-12-07

tanshinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tanshinone is a natural quinone compound found in the roots of the Chinese herb Salvia miltiorrhiza, also known as Danshen. It has garnered significant attention for its potential pharmacological activities, particularly in cardiovascular health and cancer treatment. Tanshinone exhibits various effects including:

* **Antioxidant Properties:** Tanshinone acts as a potent antioxidant, protecting cells against damage caused by free radicals. This property contributes to its potential benefits in preventing cardiovascular disease and aging-related conditions.

* **Anti-inflammatory Effects:** Studies have shown that tanshinone possesses anti-inflammatory properties, which may be beneficial in reducing inflammation associated with various diseases such as arthritis and inflammatory bowel disease.

* **Cardioprotective Effects:** Tanshinone has demonstrated cardioprotective effects by improving blood flow, reducing blood pressure, and inhibiting platelet aggregation. These properties make it a promising agent for the prevention and treatment of cardiovascular diseases.

* **Anticancer Activity:** Research suggests that tanshinone exhibits anticancer activity by inhibiting tumor growth and promoting apoptosis (programmed cell death) in various cancer cell lines.

* **Neuroprotective Effects:** Tanshinone has also been investigated for its potential neuroprotective effects, demonstrating the ability to protect neurons from damage caused by oxidative stress and inflammation.

**Importance and Research:**

Tanshinone's wide range of biological activities has driven extensive research on its potential therapeutic applications. Scientists are actively exploring its mechanisms of action, optimizing its delivery methods, and evaluating its efficacy in clinical trials. The potential of tanshinone in addressing significant health challenges makes it a highly valuable compound for pharmaceutical and medicinal research.

**Synthesis:**

Tanshinone can be extracted from the roots of Salvia miltiorrhiza or synthesized in the laboratory. Several synthetic routes have been developed to produce tanshinone, aiming to enhance its availability and purity for pharmaceutical applications.

**Note:** While tanshinone holds promising therapeutic potential, it is important to note that further research and clinical trials are necessary to fully understand its safety, efficacy, and optimal dosage for human use.'

tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
SalviagenusA genus in the mint family (LAMIACEAE).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]
Salvia miltiorrhizaspeciesA plant species which is known as an Oriental traditional medicinal plant.[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID114917
CHEMBL ID363535
CHEBI ID149906
SCHEMBL ID244391
MeSH IDM0077031

Synonyms (61)

Synonym
tanshinone
smr000445578
MLS000697676 ,
tanshinone i
tanshinon i
tanshinone a
1,6-dimethylphenanthro(1,2-b)furan-10,11-dione
c18h12o3
phenanthro(1,2-b)furan-10,11-dione, 1,6-dimethyl-
568-73-0
CHEMBL363535
aigazqphxlwmoj-uhfffaoysa-
inchi=1/c18h12o3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-8h,1-2h3
STK801472
1,6-dimethylphenanthro[1,2-b]furan-10,11-dione
CHEBI:149906
1,6-dimethylnaphtho[1,2-g][1]benzofuran-10,11-dione
1,6-dimethylnaphtho[1,2-g]benzofuran-10,11-dione
A831218
AKOS005613012
NCGC00247624-01
54693-68-4
BBL010133
03uuh3j385 ,
unii-03uuh3j385
HMS2222J14
FT-0632407
NCGC00247624-02
S2364
SCHEMBL244391
1,6-dimethyl-phenanthro(1,2-b)furan-10,11-dione
tanshinone i (constituent of chinese salvia) [dsc]
MLS006011773
bdbm51317
1,6-dimethylnaphtho[1,2-g]benzofuran-10,11-quinone
cid_114917
Q-100655
1,6-dimethylphenanthro[1,2-b]furan-10,11-dione #
phenanthro[1,2-b]furan-10,11-dione, 1,6-dimethyl-
tanshinone-i
mfcd00210563
tanshinone i, analytical standard
AC-7999
HMS3656A11
AS-68049
1,6-dimethyl-10h,11h-phenanthro[1,2-b]furan-10,11-dione
1,6-dimethyl-phenanthro[1,2-b]furan-10,11-dione
tanshinone i, >=98% (hplc)
HY-N0134
NCGC00247624-03
SW219821-1
tanshinonei
tanshinone i,(s)
BCP28292
DTXSID90972247
CCG-267206
Q27247588
tristearylorthoformate
tanshinon i, tanshinone a, tanshinquinone i
NCGC00247624-05
tanshinone i (constituent of chinese salvia)

Research Excerpts

Overview

Tanshinone IIA (TSIIA) is a phytomedicine with documented activity in treating many hepatic disorders. Tanshin one I (Tan I) is an agent with promising anti-cancer effects alone or with other drugs.

ExcerptReferenceRelevance
"Tanshinone IIA (TSIIA) is a phytomedicine with documented activity in treating many hepatic disorders."( Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis.
Abdelmonsif, DA; Ashour, AA; El-Kamel, AH; Khalifa, HM; Ramadan, AA, 2021
)
1.61
"Tanshinone IIA (TAN2A) is a major active ingredient of Salvia miltiorrhiza used in traditional Chinese medicine and tanshinone 20 (TAN20) is a derivative of TAN2A. "( Tanshinone IIA and its derivative activate thermogenesis in adipocytes and induce "beiging" of white adipose tissue.
Dong, G; Guo, X; Li, J; Ma, L; Mei, W; Xu, L; Yang, Z; Zhao, Z; Zhong, Z, 2022
)
3.61
"Tanshinone is a new fat-soluble phenanthraquinone compound derived from Salvia miltiorrhiza that can play a therapeutic role in different cancers, including PCa."( Molecular Mechanism of Tanshinone against Prostate Cancer.
Che, B; Huang, T; Li, W; Tang, K; Xu, S; Yu, Y; Zhang, W, 2022
)
1.75
"Tanshinone IIA (Tan IIA) is a therapeutic that demonstrates anti-inflammatory and antioxidative effects in rodent ischemic stroke models and stroke patients."( Tanshinone IIA-Loaded Nanoparticle and Neural Stem Cell Therapy Enhances Recovery in a Pig Ischemic Stroke Model.
Cheek, SR; Duberstein, KJ; Fagan, MM; Jeon, JH; Kaiser, EE; Kinder, HA; Kumar, A; Park, HJ; Platt, SR; Scheulin, KM; Shin, SK; Sneed, SE; Waters, ES; West, FD; Xie, J; Yang, X, 2022
)
2.89
"Tanshinone I (Tan I) is an agent with promising anti-cancer effects alone or with other drugs."( Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.
Cai, C; Cai, S; Chen, J; Hong, X; Li, D; Li, J; Li, P; Lin, E; Wang, B; Yin, Z; Zeng, G; Zhang, M; Zhao, J; Zou, B, 2022
)
1.76
"Tanshinone IIA (Tan IIA) is a pharmacologically active monomer that exerts a significant cardioprotective effect in the clinic; however, the specific mechanisms are not fully understood."( Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac function during doxorubicin-induced cardiotoxicity by activating the DAXX/MEK/ERK1/2 pathway.
He, D; Shen, L; Wang, Y; Wu, Y; Xu, L; Xu, Y, 2022
)
2.89
"Tanshinone IIA (Tan IIA) is an active component that separated from Danshen."( Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome.
Lu, F; Shen, N; Song, P; Wang, Q; Wu, Z; Xu, Y; Zhang, Y, 2022
)
2.89
"Tanshinone IIA (Tan-IIA) is a major component extracted from the traditional herbal medicine Danshen, which has shown antipulmonary fibrosis by suppress reactive oxygen species-mediated activation of myofibroblast. "( Tanshinone IIA Regulates Keap1/Nrf2 Signal Pathway by Activating Sestrin2 to Restrain Pulmonary Fibrosis.
Chen, J; Guo, C; Li, H; Wu, M; Zhai, R, 2022
)
3.61
"Tanshinone IIA is a well-known lipophilic active constituent refined from traditional Chinese medicines, danshen. "( Tanshinone IIA ameliorates myocardial ischemia/reperfusion injury in rats by regulation of NLRP3 inflammasome activation and Th17 cells differentiation.
Fan, G; Gao, S; Li, D; Yang, Z; Zhang, H, 2022
)
3.61
"Tanshinone IIA (TAN IIA) is a botanical agent with neuroprotective and antidepressant properties."( Tanshinone IIA ameliorates chronic unpredictable mild stress-induced depression-like behavior and cognitive impairment in rats through the BDNF/TrkB/GAT1 signaling pathway.
Chen, LL; Lin, L; Liu, SZ; Wang, P; Yang, J, 2023
)
3.07
"Tanshinone IIA is an extract of "( Investigation of the mechanism of tanshinone IIA to improve cognitive function via synaptic plasticity in epileptic rats.
Hua, X; Jia, C; Jiao, H; Ma, M; Wei, L; Xiao, N; Xie, J; Yin, W; Zhang, R; Zhou, S, 2023
)
2.63
"Tanshinone IIa is a key ingredient extracted from the traditional Chinese medicine Salvia miltiorrhiza (Danshen), and is widely used to treat various cardiovascular diseases. "( [Tanshinone IIa attenuates vascular calcification through inhibition of NF-κB and β-catenin signaling pathways].
Chen, JX; Chen, JY; Li, DY; Tan, X; Wang, SY; Wang, YH; Xie, YC; Zhong, H; Zhu, DX, 2022
)
3.07
"Tanshinone IIA (Tan IIA) is a lipid-soluble diterpene quinone isolated from the Chinese herb"( Renoprotective Effects of Tanshinone IIA: A Literature Review.
Chen, Z; Feng, H; Gao, H; Peng, C; Tang, S; Xie, C; Yuan, Q; Zhang, Z, 2023
)
1.93
"Tanshinone IIA (TSIIA) is a vasoactive cardioprotective drug that is widely used in studies evaluating potential therapeutic mechanisms."( The therapeutic effect of tanshinone IIA in mouse astrocytes after treatment with Angiostrongylus cantonensis fifth-stage larval excretory-secretory products.
Chen, KY; Chen, YJ; Cheng, CJ; Chiu, CH; Jhan, KY; Wang, LC, 2023
)
1.93
"Tanshinone IIA is a traditional herbal medicine which is to treat cardiovascular disease and has been shown to have various biological effects, such as anti-inflammatory, antioxidative and antitumor activities."( Tanshinone IIA inhibits endometrial carcinoma growth through the MAPK/ERK/TRIB3 pathway.
Ji, Y; Liu, M; Ma, C; Qu, P; Yu, D; Zhang, W; Zhao, J, 2023
)
3.07
"Tanshinone IIA is a promising drug for the treatment of amniotic fluid abnormality."( Tanshinone IIA changed the amniotic fluid volume and regulated expression of AQP1 and AQP3 in amniotic epithelium cells: a promising drug treating abnormal amniotic fluid volume.
Chen, B; Hua, Y; Lan, Y; Pan, S; Ying, X; Zhou, Y, 2023
)
3.07
"Tanshinone IIA (TSA) is an active ingredient derived from the rhizome of Salvia miltiorrhiza that has been found to alleviate the symptoms of several psychiatric illnesses."( Effects and mechanisms of tanshinone IIA on PTSD-like symptoms.
Hu, KB; Li, S; Liao, P; Liu, HL; Long, ZY; Lu, XM; Wang, HY; Wang, YT; Wu, QY, 2023
)
1.93
"TanshinoneⅡA (TanⅡA) is a noteworthy lipophilic diterpene compound derived from the dried roots of the Traditional Chinese Medicine Danshen () that has various pharmacological properties, including anti-inflammatory, antibacterial, and antioxidative effects. "( Protective effects of tanshinone ⅡA on sepsis-induced multiple organ dysfunction: a literature review.
Daixing, Z; Daqian, Z; Ju, F; Junshuai, W; Lili, W, 2023
)
2.67
"Tanshinone IIA is a lipophilic organic compound from the root of Danshen (Salvia miltiorrhiza) and is one of the most well-known Tanshinone molecules by pharmacologists. "( PPARG is a potential target of Tanshinone IIA in prostate cancer treatment: a combination study of molecular docking and dynamic simulation based on transcriptomic bioinformatics.
Chen, X; Ju, G; Ju, X; Xu, D; Yuan, J; Zhang, T; Zhang, Z; Zhou, J, 2023
)
2.64
"Tanshinone IIA (Tan IIA) is a diterpenoid naphthoquinone found in traditional Chinese medicine, Danshen (Salvia sp.)."( Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer.
Chen, X; Kong, X; Liu, Z; Sun, X; Zhang, R; Zhang, W; Zhu, W, 2019
)
2.68
"Tanshinone biosynthesis is a complicated process, and little is known about the third stage of the pathway."( Transcriptomic analysis reveals potential genes involved in tanshinone biosynthesis in Salvia miltiorrhiza.
Chang, Y; Li, J; Lu, S; Wang, M, 2019
)
1.48
"Tanshinone IIA (Tan IIA) is a phytochemical extracted from the Chinese herb Salvia miltiorrhiza that exhibits diverse activities."( Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.
Hu, F; Jiang, Y; Li, M; Li, Q; Shen, C; Yang, J, 2019
)
2.68
"Tanshinone IIA (TIIA) is a major component extracted from the traditional herbal medicine salvia miltiorrhiza (Danshen), which activates blood circulation and treats chronic hepatitis and liver fibrosis. "( A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis.
Dong, BS; Shi, MJ; Su, SB; Yan, XL; Yang, WN; Zhang, H, 2020
)
2.24
"Tanshinone I (TS I) is a tanshinone compound that is isolated from Danshen."( Tanshinone I induces apoptosis and protective autophagy in human glioblastoma cells via a reactive oxygen species‑dependent pathway.
Binbin, Z; Chen, L; Hongmin, C; Jian, S; Minxue, L; Ronghua, T; Shiwen, G; Xiaoxuan, F, 2020
)
2.72
"Tanshinone IIA (TSA) is a major active compound, extracted from Salvia miltiorrhiza Bunge, that possesses various pharmacological activities."( Tanshinone IIA alleviates hypoxia/reoxygenation induced cardiomyocyte injury via lncRNA AK003290/miR-124-5p signaling.
Chen, L; Liu, G; Shi, H; Wei, L; Yu, Q, 2020
)
2.72
"Tanshinones are an important type of natural products isolated from Salvia miltiorrhiza Bunge with various bioactivities. "( Tanshinones: An Update in the Medicinal Chemistry in Recent 5 Years.
Cui, S; He, J; Lai, Z; Zhao, H; Zhou, C, 2021
)
3.51
"Tanshinone IIA (TSIIA) is a promising phytomedicine that has been extensively studied due to its numerous biological activities, especially as an anticancer drug. "( Enhanced oral bioavailability of Tanshinone IIA using lipid nanocapsules: Formulation, in-vitro appraisal and pharmacokinetics.
Abdelmonsif, DA; Ashour, AA; El-Kamel, AH; Ramadan, AA, 2020
)
2.28
"Tanshinones are a class of bioactive compounds present in the Chinese herbal medicine Danshen (Salvia miltiorrhiza Bunge), containing among others, abietane diterpene quinone scaffolds. "( Synthesis and Biological Activity Study of Tanshinone Derivatives: A Literature and Patent Review.
Chang, J; Huang, H; Song, C, 2020
)
2.26
"Tanshinone IIA (Tan IIA) is a pharmacologically active lipophilic component of Salvia miltiorrhiza extract."( Prospective therapeutic potential of Tanshinone IIA: An updated overview.
Almatroudi, A; Alzohairy, MA; Amirizadeh, M; Ansari, MA; Equbal, MJ; Hoque, M; Khan, FB; Rehman, S; Safdari, HA; Safdari, M, 2021
)
1.62
"Tanshinones are a class of lipophilic phenanthrene compounds found in the roots of"( The Skeletal Effects of Tanshinones: A Review.
Chin, KY; Ekeuku, SO; Pang, KL, 2021
)
1.65
"Tanshinone (Tan)-IIA is a derivative of phenanthrenequinone and the main active ingredient isolated from Salviae miltiorrhizae radix (Danshen). "( Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1α, CHOP, caspase‑3 and caspase‑12 in pancreatic cancer BxPC‑3 cell‑derived xenograft tumors.
Chiu, TL; Su, CC, 2017
)
3.34
"Tanshinone IIA is a known small molecule activator of bone morphogenetic protein (BMP) signaling."( Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells.
Heo, JS; Kim, HO; Lee, SG, 2017
)
1.18
"Tanshinone IIA (Tan IIA) is a constituent of Danshen Salvia miltiorrhiza Bunge (Lamiaceae); however, its antifatigue activity remains unclear."( Antifatigue properties of tanshinone IIA in mice subjected to the forced swimming test.
Chang, TW; Chen, EL; Chen, MH; Chen, TI; Chiang, YC; Jhang, YS; Lai, SC; Lin, CY; Lin, IH; Seenan, V; Shiung, J; Tseng, YW; Tzeng, YJ, 2017
)
2.2
"Tanshinone I (TSI) is a lipophilic diterpene in Salvia miltiorrhiza with versatile pharmacological activities. "( Metabolic characteristics of Tanshinone I in human liver microsomes and S9 subcellular fractions.
Fan, Y; Hu, Y; Jiang, J; Li, GF; Li, Y; Qiu, F; Su, H; Tan, B; Wang, Q, 2019
)
2.25
"Tanshinone IIA is a chemical compound extracted from Salvia miltiorrhiza Bunge, a perennial plant also known as red sage used in traditional Chinese medicine. "( Tanshinone IIA Attenuates Contrast-Induced Nephropathy via Nrf2 Activation in Rats.
Cheng, D; Jian, G; Liang, R; Wang, F; Wang, N; Zhang, G; Zhao, Q, 2018
)
3.37
"Tanshinone IIA (Tan‑IIA) is a potential agent for the treatment of cardiovascular and cerebrovascular diseases."( Tanshinone IIA improves hypoxic ischemic encephalopathy through TLR‑4‑mediated NF‑κB signal pathway.
Fang, C; Fu, C; Liu, C; Liu, H; Xie, L; Ye, W; Zhang, B, 2018
)
2.64
"Tanshinone IIA (TIIA) is an active compound that can be isolated from the Chinese herb, Salvia miltiorrhizae Bunge, also known as danshen. "( Tanshinone IIA attenuates paraquat‑induced acute lung injury by modulating angiotensin‑converting enzyme 2/angiotensin‑(1‑7) in rats.
Chen, J; Li, Z; Liu, M; Niu, W; Sun, X; Wang, Y; Wu, H, 2018
)
3.37
"Tanshinone IIA is an effective compound to suppress cell proliferation and promote cell apoptosis."( High-Dose Tanshinone IIA Suppresses Migration and Proliferation While Promoting Apoptosis of Astrocytoma Cells Via Notch-1 Pathway.
Chen, X; Dong, W; Jia, Y; Zhang, Y, 2018
)
1.6
"Tanshinone IIA (TIIA) is a diterpenoid naphthoquinone isolated from the herb Salvia miltiorrhiza with antitumor effects manifested at multiple levels that are mechanistically obscure. "( HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone IIA in human osteosarcoma cells.
Chiang, JH; Fong, YC; Huang, HS; Huang, ST; Su, YC; Wu, YY; Yen, JH, 2018
)
2.15
"Tanshinone IIA-NP is a novel approach to treat myocardial IR injury in patients with MI."( Nanoparticle-mediated delivery of Tanshinone IIA reduces adverse cardiac remodeling following myocardial infarctions in a mice model: role of NF-κB pathway.
Chen, P; Guo, R; Lan, Y; Mao, S; Wang, L; Zhang, M, 2018
)
1.48
"Tanshinone I is an important plant-derived natural product that has been reported to exert impressive bioactivities, including antiproliferative effects against different types of cancer cells. "( Tanshinone l exhibits anticancer effects in human endometrial carcinoma HEC-1-A cells via mitochondrial mediated apoptosis, cell cycle arrest and inhibition of JAK/STAT signalling pathway.
Cao, Q; Hou, X; Li, Q; Liang, Y; Ma, X; Mu, W; Zhang, J,
)
3.02
"Tanshinone IIA is an interesting agent with potential to treat drug-resistant gastric cancer in combination therapy."( Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA.
Chen, L; Gu, C; Jiang, H; Jin, Y; Luan, J; Shen, J; Wang, L; Wu, Y; Xiao, Z; Xu, Z; Zhang, W; Zhou, D; Zhu, Y; Zuo, J, 2018
)
2.14
"Tanshinone IIA is an important traditional Chinese medicine monomer and has been shown to have remarkable protective effect against HF."( Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway.
Chen, X; Guo, D; Li, C; Shao, M; Wang, Q; Wang, W; Wang, X; Wang, Y; Wu, Y; Zhang, Q; Zhang, X, 2019
)
2.68
"TanshinoneⅡA (TAN2A) is a major active component of Salvia miltiorrhiza, a traditional anti-inflammatory cardiovascular medicine."( TanshinoneⅡA phenanthroimidazole derivative polarizes macrophage to improve metabolic homeostasis.
Gao, G; Gong, B; Li, Q; Luo, S; Ma, L; Mei, W; Qi, W; Xu, L; Yang, X; Yang, Z; Zhao, Z; Zhou, L; Zhou, T, 2019
)
2.68
"Tanshinone I (Tan I) is a widely used diterpene compound derived from the traditional Chinese herb Danshen. "( Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway.
Chen, S; Ding, Z; Li, J; Li, Y; Miao, J; Wang, J; Wang, W, 2019
)
3.4
"Tanshinone II A is a main lipid-soluble monomer derivative from the root of Salvia miltiorrhiza (Danshen) and tanshinone II A possess a variety of biological activities through redox signaling pathway."( Tanshinone II A inhibits tat-induced HIV-1 transactivation through redox-regulated AMPK/Nampt pathway.
Chen, XY; Wu, TC; Zhang, FJ; Zhang, HS, 2014
)
2.57
"Tanshinone I (TsI) is an important lipophilic diterpene extracted from Danshen (Radix Salvia miltiorrhizae) and has been used in Asia for the treatment of cerebrovascular diseases such as ischemic stroke. "( Anti-inflammatory effect of tanshinone I in neuroprotection against cerebral ischemia-reperfusion injury in the gerbil hippocampus.
Ahn, JH; Chen, BH; Cho, JH; Choi, JH; Hwang, IK; Kim, IH; Kwon, SH; Lee, CH; Lee, JC; Lee, YL; Park, JH; Park, Ok; Won, MH; Yan, BC; Yoo, KY, 2014
)
2.14
"Tanshinone is a group of active diterpenes, which are widely used in the treatment of cardiovascular disease. "( Effects of methyl jasmonate and salicylic acid on tanshinone production and biosynthetic gene expression in transgenic Salvia miltiorrhiza hairy roots.
Cui, L; Hao, X; Kai, G; Shi, M; Xu, C; Zhang, Y,
)
1.83
"Tanshinone IIA is a pharmacologically active ingredient extracted from Danshen, a Chinese traditional medicine. "( A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking and drug repurposing.
Chen, SJ, 2014
)
2.16
"Tanshinone IIA (Tan IIA) is a diterpenoid naphthoquinone found in the traditional Chinese medicine Danshen (Salvia sp.)."( Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Aqil, F; Gupta, RC; Jeyabalan, J; Munagala, R, 2015
)
2.58
"Tanshinone IIA is a lipophilic abietane diterpene compound, which exhibits protective effects against ischaemia/reperfusion injury; however, the pathways responsible for the myocardial protective activities of tanshinone IIA remain to be elucidated. "( Janus kinase/signal transducer and activator of transcription inhibitors enhance the protective effect mediated by tanshinone IIA from hypoxic/ischemic injury in cardiac myocytes.
Chen, H; Pang, LX; Shen, Y; Sun, RH; Tu, JF; Yang, XH; Zhang, MQ; Zheng, YL, 2015
)
2.07
"Tanshinone IIA (TSA) is a lipid soluble agent derived from the root of Salvia miltiorrhiza (Danshen). "( Tanshinone IIA attenuates the cerebral ischemic injury-induced increase in levels of GFAP and of caspases-3 and -8.
Bondy, SC; Jian, L; Li, W; Luo, H; Wen, P; Yang, F; Zhou, J; Zhou, L, 2015
)
3.3
"Tanshinone IIA (TIIA) is a diterpene quinone extracted from the plant Danshen (Salvia miltiorrhiza) used in traditional Chinese herbal medicine. "( Integrating transcriptomics and proteomics to show that tanshinone IIA suppresses cell growth by blocking glucose metabolism in gastric cancer cells.
Hsia, CR; Hsu, CL; Huang, HC; Juan, HF; Lin, LL, 2015
)
2.11
"Tanshinone IIA (T2A) is a novel antiangiogenic agent with promising antitumor effects; however, the molecular mechanism underlying the antiangiogenic effects of T2A remains unclear."( Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
Chen, Y; Cui, H; Gao, N; Hu, X; Li, G; Liu, L; Shan, C; Zhou, J; Zhou, T, 2015
)
2.58
"Tanshinone ⅡA (Tan ⅡA) is a lipophilic diterpene extracted from the Chinese herb Salvia miltiorrhiza Bunge with diverse biological functions."( Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats.
Feng, Z; Gao, L; He, H; Lin, H; Tang, H; Wu, T; Wu, Y, 2015
)
2.58
"Tanshinone IIA (TSIIA) is an active constituent of the traditional Chinese medicinal plant Salvia miltiorrhiza that is known to have anti-tumor properties. "( Targeted delivery of tanshinone IIA-conjugated mPEG-PLGA-PLL-cRGD nanoparticles to hepatocellular carcinoma.
Cai, J; Costanza, F; Fan, Z; Ji, G; Li, Q; Song, D; Wang, Y, 2014
)
2.16
"Tanshinone (TA) is a derivative of phenanthrenequinone isolated from Danshen, which is suggested to inhibit tumor growth by inducing apoptosis in tumor cells."( Radix Astragali and Tanshinone Help Carboplatin Inhibit B16 Tumor Cell Growth.
Wu, J; Xu, H; Zhang, L; Zhang, X, 2016
)
1.48
"Tanshinone ⅡA (Tan ⅡA) is a Traditional Chinese Medicine commonly used in Asian and Western countries for the prevention and treatment of cardiovascular disorders, such as atherosclerosis. "( Protective effects of tanshinone ⅡA on endothelial progenitor cells injured by tumor necrosis factor-α.
Pan, YY; Wang, XX; Yang, JX; Zhang, YF, 2015
)
2.17
"Tanshinone IIA is a constituent of Danshen; a traditional Chinese medicine used in the treatment of cardiovascular diseases."( Tanshinone IIA enhances bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in nuclei and mitochondria.
Dong, X; He, A; Jiang, H; Johansson, M; Karlsson, A; Zhao, L; Zheng, C; Zheng, X, 2015
)
2.58
"Tanshinone IIA (TSA) is a lipophilic diterpene purified from the Chinese herb Danshen, which exhibits potent antioxidant and anti-inflammatory properties. "( Effects of Tanshinone IIA on osteogenic differentiation of mouse bone marrow mesenchymal stem cells.
Dai, T; Qian, K; Shi, K; Xu, H, 2015
)
2.25
"Tanshinones are a group of bioactive constituents isolated from Salvia miltiorrhiza Bunge, a widely prescribed traditional Chinese herb. "( Total Tanshinones-Induced Apoptosis and Autophagy Via Reactive Oxygen Species in Lung Cancer 95D Cells.
Chen, X; Gao, H; Hao, W; Leung, CH; Lu, J; Sun, W; Zhao, W, 2015
)
2.34
"Tanshinone IIA is a pharmacologically active compound isolated from Danshen (Salvia miltiorrhiza), a traditional Chinese herbal medicine for the management of cardiac diseases and other disorders. "( Drug-target networks for Tanshinone IIA identified by data mining.
Chen, SJ, 2015
)
2.16
"Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Danshen."( [Research progress in the study of protective effect of tanshinone IIA on cerebral ischemic stroke].
Bao, XQ; Li, DC; Sun, H; Zhang, D, 2015
)
1.38
"Tanshinone IIA (TanIIA) is a traditional Chinese agent and has been widely used for treatment of cardiovascular diseases. "( Tanshinone IIA inhibits acute promyelocytic leukemia cell proliferation and induces their apoptosis in vivo.
Li, J; Meng, W; Xing, H; Yang, Y; Zhang, K, 2016
)
3.32
"Tanshinone IIA is an active compound in Danshen and is structurally similar to 17[Formula: see text]-estradiol (E[Formula: see text]."( Tanshinone IIA Prevents Leu27IGF-II-Induced Cardiomyocyte Hypertrophy Mediated by Estrogen Receptor and Subsequent Akt Activation.
Chung, LC; Hsieh, DJ; HsuanDay, C; Huang, CY; Jong, GP; Kuo, WW; Lai, CH; Pai, PY; Wang, HF; Weng, YS, 2015
)
2.58
"Tanshinone IIA (Tan IIA) is a well-known flavonoid that elicits an important therapeutic effect by inhibiting inflammatory response."( Anti-Inflammatory Activity of Tanshinone IIA in LPS-Stimulated RAW264.7 Macrophages via miRNAs and TLR4-NF-κB Pathway.
Fan, G; Fordjour, PA; Gao, X; Jiang, X; Miao, L; Wu, X; Zhang, H; Zhu, Y, 2016
)
1.44
"Tanshinones is a kind of diterpene quinone compounds with important pharmacological activities from traditional Chinese medicine Salvia miltiorrhiza."( Research progress of synthetic biology for tanshinones.
Dai, ZB; Gao, W; Guo, J; Hu, TY; Huang, LQ; Lv, DM; Zhou, YJ, 2015
)
1.4
"Tanshinone IIA (TSA) is a widely used traditional Chinese medicine, which has been demonstrated to protect damaged liver cells and is currently administered in the treatment of liver fibrosis. "( Tanshinone IIA promotes the proliferation of WB-F344 hepatic oval cells via Wnt/β-catenin signaling.
Jia, J; Li, X; Wang, B; You, H; Ze, X; Zhang, D; Zhao, X, 2016
)
3.32
"Tanshinone IIA is an active component of the traditional Chinese medicine. "( Tanshinone IIA affects the HDL subfractions distribution not serum lipid levels: Involving in intake and efflux of cholesterol.
Cao, HM; Chen, WN; Jia, LQ; Ren, L; Song, N; Wang, JY; Xu, Y; Yang, GL; Zhang, N; Zhu, ML, 2016
)
3.32
"Tanshinone IIA is a diterpene extracted from Salvia miltiorrhiza, a popular and safe herb medicine that has been widely used in China and other Asian countries. "( Tanshinone IIA Protects Against Folic Acid-Induced Acute Kidney Injury.
Jiang, C; Jin, B; Shao, Q; Xu, B; Yan, X; Zhang, M; Zhu, W, 2016
)
3.32
"Tanshinone IIA is an active compound of Salvia miltiorrhiza Bge."( Inflammatory and Apoptotic Regulatory Activity of Tanshinone IIA in Helicobacter pylori-Infected Cells.
Chen, GY; Chuang, DY; Shu, YC; Wang, YC, 2016
)
1.41
"Tanshinone IIA (TSN IIA) is a bioactive constituent of the traditional Chinese medicine Danshen, which has been reported to have an antinociceptive effect on neuropathic and inflammatory pain through downregulation of the late proinflammatory cytokine high-mobility group protein B1 (HMGB1)."( Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain.
Chen, L; Hao, W; Kaye, AD; Niu, JX; Wu, LF; Xu, SY; Yang, F,
)
2.3
"Tanshinone II A (TSIIA) is a diterpene quinone extracted from the roots of Salvia miltiorrhiza with anti-inflammatory and anti‑oxidant properties that is used to treat atherosclerosis. "( Tanshinone II A stabilizes vulnerable plaques by suppressing RAGE signaling and NF-κB activation in apolipoprotein-E-deficient mice.
Li, H; Tong, L; Wan, Y; Zhang, L; Zhang, T; Zhao, D, 2016
)
3.32
"Tanshinone IIA is a key active ingredient of danshen, which is derived from the dried root or rhizome of Salviae miltiorrhizae Bge. "( Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways.
Han, R; Tang, Q; Wang, G; Zhu, Y, 2017
)
3.34
"Tanshinone IIA (Tan IIA) is a compound isolated from Salvia miltiorrhiza Bunge (Danshen). "( Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest.
Chan, WK; Chang, DC; Luo, H; Luo, KQ; Xiao, K; Xu, N; Zhou, L, 2008
)
3.23
"Tanshinone IIA is an important ingredient in the herb danshen (Salvia miltiorrhiza), which has been used to treat cardiovascular diseases such as atherosclerosis and angina for hundreds of years in China. "( Tanshinone IIA reduces macrophage death induced by hydrogen peroxide by upregulating glutathione peroxidase.
Elmer, G; Leboeuf, RC; Li, YI, 2008
)
3.23
"Tanshinone IIA (Tan) is a lipophilic diterpene that is widely used to treat cardiovascular diseases in traditional Chinese medicine, and has recently been found to reduce body weight and lower blood lipids."( The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism.
Gong, Z; Huang, C; Li, Q; Peng, L; Sheng, X; Wang, MW; Zang, YQ; Zhang, Y, 2009
)
1.45
"Tanshinone IIB (TSB) is a major constituent of Salvia miltiorrhiza, which is widely used in treatment of cardiovascular and central nervous system (CNS) diseases such as coronary heart disease and stroke. "( Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
Chen, X; Liang, J; Wen, JY; Yu, XY; Zhou, SF; Zhou, ZW, 2007
)
2
"Tanshinone IIA (Tan IIA) is a major compound extracted from a traditional herbal medicine Salvia miltiorrhiza BUNGE, which is used to treat cardiovascular diseases, cerebrovascular diseases and postmenopausal syndrome. "( The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS.
Fan, GW; Gao, XM; Hu, LM; Kang, LY; Su, YF; Wang, H; Zhang, BL; Zhang, J; Zhu, Y, 2009
)
2.07
"Tanshinone IIA is an active component of a traditional Chinese medicine based on Salvia miltiorrhiza, which reduces sudden cardiac death by suppressing ischaemic arrhythmias. "( Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1.
Cai, B; Chu, W; Li, B; Li, X; Lu, Y; Pan, Z; Qiao, G; Shan, H; Xu, C; Yang, B; Zhang, L; Zhang, Y, 2009
)
3.24
"Tanshinone IIA is a widely used Chinese herbal medicine isolated from Danshen (Salvia miltiorrhiza). "( Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer.
Chen, J; Lu, Q; Zhang, P; Zhang, X, 2009
)
2.05
"Tanshinone II-A is an alcohol extract of the root of the traditional Chinese medicinal plant Salvia miltiorrhiza Bunge, whose effects and mechanism in tumor metastasis are still unclear. "( Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo.
Feng, T; Ren, L; Yuxian, X; Zhengcai, L,
)
3.02
"Tanshinone I (Tan-I) is a diterpene quinone extracted from the traditional herbal medicine Salvia miltiorrhiza Bunge. "( Down-regulation of telomerase activity and activation of caspase-3 are responsible for Tanshinone I-induced apoptosis in monocyte leukemia cells in vitro.
Fan, RF; Fang, ZG; Guan, WB; Huang, HQ; Huang, RW; Lin, DJ; Liu, JJ; Liu, PQ; Liu, XD; Xiao, RZ; Yang, HZ; Zhang, Y, 2010
)
2.03
"Tanshinone IIA is a fat-soluble pharmacologically active ingredient of Danshen, a well-known traditional Chinese medicine used for cardiovascular diseases such as coronary heart disease. "( Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes.
Chu, W; Li, B; Li, X; Lu, Y; Shan, H; Wang, B; Yang, B; Zhang, J; Zhang, L; Zhang, Y; Zhao, M, 2010
)
3.25
"Tanshinones are a series of abietane diterpenes, isolated exclusively from Salvia miltiorrhiza and related species. "( Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents.
Dong, Y; Lee, KH; Morris-Natschke, SL, 2011
)
2.06
"Tanshinone IIA is a lipid-soluble compound extracted from Chinese herb Danshen which was commonly used in the treatment of cerebrovascular diseases. "( Tanshinone IIA prevented brain iron dyshomeostasis in cerebral ischemic rats.
Bi, Z; Cai, B; Lu, Y; Shan, H; Yang, L; Yin, L; Zhang, B; Zhang, L, 2011
)
3.25
"Tanshinone is a group of active diterpenes widely used in treatment of cardiovascular diseases. "( Metabolic engineering tanshinone biosynthetic pathway in Salvia miltiorrhiza hairy root cultures.
Kai, G; Liao, P; Luo, X; Xiao, J; Xu, H; You, L; Zhang, L; Zhou, C, 2011
)
2.13
"Tanshinone IIA is a lipid-soluble pharmacologically active compound extracted from the rhizome of the Chinese herb Salvia miltiorrhiza, a well-known traditional Chinese medicine used for the treatment of cardiovascular disorders."( Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.
Cai, B; Chen, N; Dong, D; Li, J; Li, X; Liu, Y; Lu, Y; Shan, H; Tan, X; Wang, G; Wang, X; Yang, B; Yang, F; Zhang, P, 2011
)
2.53
"Tanshinone A is a novel derivative of phenanthrene-quinone extracted from Salvia miltiorrhiza BUNGE, a traditional herbal medicine. "( Cytotoxic effect and apoptotic mechanism of tanshinone A, a novel tanshinone derivative, on human erythroleukemic K562 cells.
Cen, J; Guan, T; Li, YM; Tang, XZ; Yan, F; Zhen, X, 2011
)
2.07
"Tanshinone IIA (TA) is a major active component of Danshen (Salvia miltiorrhiza bunge), a well-known traditional Chinese medicine. "( Preparation, characterization and cytotoxicity evaluation of tanshinone IIA nanoemulsions.
Chang, LC; Chuo, WH; Li, PC; Liu, CW; Tsai, TR; Wu, CL, 2011
)
2.05
"Tanshinone IIA (Tan IIA) is an active ingredient extracted from the widely used Danshen root (Salvia miltiorrhiza Bunge), a traditional Chinese medicine. "( Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro.
Cai, L; Hu, H; Jin, W; Wei, RX; Zhang, Y; Zhu, XB, 2012
)
3.26
"Tanshinone IIA (Tan IIA) is a diterpene quinone extracted from the root of Salvia miltiorrhiza, a Chinese traditional herb. "( Analysis of tanshinone IIA induced cellular apoptosis in leukemia cells by genome-wide expression profiling.
Chen, S; Huang, L; Li, J; Liu, C; Meng, F; Wang, L; Wu, F; Xiao, B; Xu, Y; Yang, M; Ye, J, 2012
)
2.2
"Tanshinone IIA (TIIA) is an important component of Danshen, a traditional Chinese medicine that has been commonly used to treat cardiovascular disease."( Anti-nociceptive effects of Tanshinone IIA (TIIA) in a rat model of complete Freund's adjuvant (CFA)-induced inflammatory pain.
Cao, F; Li, Y; Luo, D; Ni, L; Sun, S; Yin, X; Yin, Y; Zhang, T, 2012
)
1.39
"Tanshinone IIA is a lipid-soluble pharmacologically active compound extracted from the rhizome of Chinese herb Salvia miltiorrhiza, a well-known traditional Chinese medicine used for the treatment of cardiovascular disorders. "( Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes.
Li, X; Li, Y; Shan, H; Wang, H; Wu, Y; Xing, S; Xu, C; Zhang, L; Zhang, Y; Zhang, Z; Zhu, D, 2012
)
3.26
"Tanshinone IIA is a good candidate for treating cerebral ischemia, but its short half-life and poor permeability across the blood-brain-barrier (BBB) limit its curative efficacy. "( Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia.
An, C; Jin, P; Liu, X; Wang, L, 2013
)
2.06
"Tanshinones are a class of abietane diterpene compound isolated from Salvia miltiorrhiza (Danshen or Tanshen in Chinese), a well-known herb in Traditional Chinese Medicine (TCM). "( Tanshinones: sources, pharmacokinetics and anti-cancer activities.
Jiang, C; Jiang, P; Kim, SH; Lü, J; Ye, M; Zhang, Y, 2012
)
3.26
"Tanshinone I was found to be an inhibitor of type IIA human recombinant sPLA(2)(IC(50) = 11 microM) and rabbit recombinant cPLA(2) (IC(50) = 82 microM)."( Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses.
Chang, HW; Kang, SS; Kim, HP; Kim, SY; Moon, TC; Son, KH, 2002
)
1.43
"Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Salvia miltiorrhiza BUNGE, which is a traditional herbal medicine that is used to treat cardiovascular diseases. "( [Anticancer effect of tanshinone and its mechanisms].
Wang, XJ; Wei, YQ; Yuan, SL, 2003
)
2.08
"Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Danshen, a widely used Chinese herbal medicine. "( Potential anticancer activity of tanshinone IIA against human breast cancer.
Liu, G; Lu, Y; Wang, W; Wang, X; Wei, Y; Yuan, S; Zhang, J, 2005
)
2.05
"Tanshinone IIA is a compound purified from the Chinese herb Danshen (Radix Salviae Miltiorrhiza Bge). "( Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage.
Chan, WY; Chik, KW; Fok, TF; Fung, KP; Gu, GJ; Li, K; Ng, HK; Ng, PC; Wang, CC; Woo, KS; Xia, WJ; Yang, M, 2005
)
2.02
"Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Danshen, a widely used Chinese herbal medicine. "( Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells.
Jiang, S; Lin, P; Lu, Y; Ren, J; Wang, J; Wang, Q; Wang, X; Wu, Y; Xiong, Z; Yang, H; Yuan, S; Zhang, J, 2007
)
2.02
"Tanshinone IIB (TSB) is a major active constituent of the root of Salvia miltiorrhiza (Danshen) used in the treatment of acute stroke. "( Tanshinone IIB, a primary active constituent from Salvia miltiorrhza, exhibits neuro-protective activity in experimentally stroked rats.
Chan, E; Chen, X; Chowbay, B; Duan, W; Li, CG; Liang, J; Lin, SG; Sheu, FS; Wen, JY; Yu, XQ; Yu, XY; Zhou, SF; Zhou, ZW, 2007
)
3.23
"Tanshinones are a class of bioactive constituents in the roots of Salvia miltiorrhiza named Dan-Shen in Chinese, which possess diverse pharmacological activities. "( Profiling the metabolic difference of seven tanshinones using high-performance liquid chromatography/multi-stage mass spectrometry with data-dependent acquisition.
Guo, D; Han, J; Liu, P; Ma, X; Sun, J; Wang, B; Xu, M; Yang, M, 2007
)
2.04
"Tanshinone IIA (TSA) is a major constituent of Salvia miltiorrhiza Bunge widely used in the treatment of stroke. "( Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier.
Chen, X; Li, XX; Xue, CC; Zhou, SF; Zhou, ZW, 2007
)
2.02
"Tanshinones are a group of diterpenoids found in the roots of Salvia miltiorrhiza Bunge which has been used to treat cardiac disease. "( Tanshinone congeners improve memory impairments induced by scopolamine on passive avoidance tasks in mice.
Cheong, JH; Jeon, SJ; Jung, JW; Kang, SS; Kim, DH; Kim, YS; Ko, KH; Lee, S; Ryu, JH; Shin, BY; Son, KH; Yoon, BH, 2007
)
3.23
"Tanshinone IIA (Tan IIA) is a member of the major lipophilic components abstracted from the root of Salvia miltiorrhiza Bunge and has the capacity of anti-atherosclerosis. "( Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit.
Fang, ZY; Lin, R; Liu, Y; Yang, GD; Yuan, BX; Zhang, H, 2008
)
3.23
"Tanshinone IIA (TSIIA) is a major active triterpenoid isolated from Salvia miltiorrhiza. "( Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases.
Bi, HC; Chen, X; Deng, Y; Gu, LQ; Huang, M; Huang, ZY; Liu, PQ; Pan, Y; Sun, HY; Wen, YY; Xu, CS; Zhao, LZ; Zhou, SF; Zuo, Z, 2008
)
2.03
"Tanshinone IIA (TSN) is a monomer extracted from the Chinese herb Danshen. "( Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis.
Chen, S; Gao, J; Le, K; Li, R; Liu, P; Pi, R; Wang, P; Yang, G; Zhang, H, 2008
)
3.23
"Tanshinone IIB (TSB) is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used in the treatment of stroke and coronary heart disease in Asian countries. "( Tanshinone IIB, a primary active constituent from Salvia miltiorrhiza, exerts neuroprotective effect via inhibition of neuronal apoptosis in vitro.
Li, CG; Xue, CC; Yu, XQ; Zhou, SF; Zhou, ZW, 2008
)
3.23
"Tanshinone II-A is a derivative of phenanthrene-quinone isolated from Salvia miltiorrhiza BUNGE, a traditional herbal medicine that is known to induce antiinflammatory, anti-oxidative and cytotoxic activity. "( Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3.
An, KS; Choi, SM; Sung, HJ; Yoon, Y, 1999
)
3.19
"Tanshinone II-A (TSII-A) is a major component of Salvia miltorrhiza Bunge which has long been used for preventing and ameliorating anginal pain in China. "( Tanshinone II-A inhibits low density lipoprotein oxidation in vitro.
Hirota, Y; Hoshiai, K; Ichimori, K; Li, M; Nakazawa, H; Niu, XL; Yang, X, 2000
)
3.19

Effects

Tanshinone IIA has a protective effect on the nerve of septic mice. Its mechanism may be related to the anti-inflammatory effects of the peripheral and hippocampal parts. Tanshin one I has a good absorbing in the rat small intestine.

Tanshinone IIA (Tan IIA) has been reported for neuroprotective potential to against amyloid β peptides (Aβ)-induced cytotoxicity. Tanshinones have been identified as a novel class of Nrf2-inducers for antioxidant tissue protection.

ExcerptReferenceRelevance
"Tanshinone IIA (Tan IIA) has an important role in treatment of cardiovascular diseases, including atherosclerosis. "( Tan IIA mitigates vascular smooth muscle cell proliferation and migration induced by ox-LDL through the miR-137/TRPC3 axis.
Gao, Z; Guan, QL; Li, W, 2023
)
2.35
"Tanshinone IIA has a protective effect on the nerve of septic mice, and its mechanism may be related to the anti-inflammatory effects of the peripheral and hippocampal parts as well as inhibiting the over-activation of astrocytes and microglia."( The Protective Effects and the Involved Mechanisms of Tanshinone IIA on Sepsis-Induced Brain Damage in Mice.
Guo, NZ; Wu, J; Xiong, CQ; Zhou, HC, 2019
)
1.48
"Tanshinone I has a good absorbing in the rat small intestine."( [Absorption mechanism of tanshinone II A, cryptotanshinone, tanshinone I and tanshinones extract in rat small intestine in vivo].
Du, S; Li, X; Wu, Q; Yan, H; Yang, Y; Zhou, L, 2010
)
1.39
"Tanshinone II A has an inhibitive effect on the proliferation of K562 cells and an inductive effect on the differentiation of erythrocyte series. "( [Study on the differentiation of K562 cell-line induced by Tanshinone II A].
Jia, Y; Li, Y; Liu, T; Meng, W; Wu, Y; Yang, Y, 2002
)
2
"Tanshinone IIA has been indicated to ameliorate streptozotocin-induced DN."( Tanshinone IIA down-regulates -transforming growth factor beta 1 to relieve renal tubular epithelial cell inflammation and pyroptosis caused by high glucose.
Deng, X; Li, Y; Lv, X; Xue, H; Zhu, S; Zhuang, W, 2022
)
2.89
"Tanshinone IIA (Tan IIA) has an important role in treatment of cardiovascular diseases, including atherosclerosis. "( Tan IIA mitigates vascular smooth muscle cell proliferation and migration induced by ox-LDL through the miR-137/TRPC3 axis.
Gao, Z; Guan, QL; Li, W, 2023
)
2.35
"Tanshinone IIA (Tan IIA) has anti-inflammatory, antioxidant, and anti-apoptotic activities."( Tanshinone IIA inhibits ischemia-reperfusion-induced inflammation, ferroptosis and apoptosis through activation of the PI3K/Akt/mTOR pathway.
Ge, B; Liu, Y; You, J; Zhang, R,
)
2.3
"Tanshinone IIA (Tan IIA) has antitumor activity in vitro and in vivo."( Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei, Q; Teng, Z; Xu, S, 2020
)
2.72
"Tanshinone IIA (Tan IIA) has been revealed to effectively inhibit angiogenesis in CRC, although the underlying mechanism remains to be determined."( Tanshinone IIA reduces secretion of pro‑angiogenic factors and inhibits angiogenesis in human colorectal cancer.
Feng, Y; Fu, J; Ji, Q; Jia, R; Li, Q; Li, Y; Liu, N; Sui, H; Wang, T; Wang, Y; Zhang, B; Zhang, Z; Zhou, L, 2020
)
2.72
"Tanshinone IIA (tan) has been used to protect the cardiovascular system for hundreds of years."( Tanshinone IIA elevates serum soluble klotho levels and decreases cardiovascular events in patients on maintenance hemodialysis: a prospective before-after study.
Cao, J; Ding, H; Li, H; Xu, Q; Zhang, X, 2020
)
2.72
"Tanshinone IIa (TSA) has been approved to treat cardiovascular diseases by the China State Food and Drug Administration. "( The protective effect of tanshinone IIa on endothelial cells: a generalist among clinical therapeutics.
Feng, J; He, Y; Liu, L; Wang, J; Yao, F; Zhou, D, 2021
)
2.37
"Tanshinone IIA has been reported to exhibit anti-inflammatory effects, while it is not clear whether Tanshinone IIA has protective role in vitiligo. "( Tanshinone IIA alleviates vitiligo by suppressing AKT mediated CD8
Li, G; Wang, Y; Zhang, B; Zhang, D, 2021
)
3.51
"As Tanshinone IIA (TIIA) has potent anti-oxidant and anti-inflammatory activities, we used the adjuvant-induced arthritis (AA) murine model of RA to investigate the impact of TIIA on RA and immune cell activation."( Tanshinone IIA ameliorates chronic arthritis in mice by modulating neutrophil activities.
Huang, G; Luo, G; Sheng, H; Xu, A; Yu, R; Yuan, K; Zhang, S; Zhu, Q, 2017
)
2.41
"Tanshinone IIA (Tan IIA) has been used to treat various circulatory disturbance-related diseases because of its pharmacological actions, including vasodilation."( Tanshinone IIA ameliorated endothelial dysfunction in rats with chronic intermittent hypoxia.
Chang, Y; Chen, L; Guo, QH; Ji, ES; Li, AY; Zhao, YS,
)
2.3
"Tanshinone IIA has been shown to protect against various organ injuries."( Tanshinone IIA Attenuates Contrast-Induced Nephropathy via Nrf2 Activation in Rats.
Cheng, D; Jian, G; Liang, R; Wang, F; Wang, N; Zhang, G; Zhao, Q, 2018
)
2.64
"TanshinoneIIA (TanIIA) has been demonstrated to possess numerous biological effects. "( TanshinoneIIA Alleviates Inflammatory Response and Directs Macrophage Polarization in Lipopolysaccharide-Stimulated RAW264.7 Cells.
Fan, G; Gao, S; Guo, Y; Li, D; Mao, J; Wang, Y; Xu, S; Zhu, M, 2019
)
3.4
"Tanshinone IIA has been reported to play an important role in treating multiple diseases; yet, whether Tanshinone IIA can be an irradiation sensitizer has not been reported."( Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway.
Chen, L; Hao, YL; Xu, FW; Xu, H; Xu, LN, 2018
)
2.64
"Tanshinone IIA has a protective effect on the nerve of septic mice, and its mechanism may be related to the anti-inflammatory effects of the peripheral and hippocampal parts as well as inhibiting the over-activation of astrocytes and microglia."( The Protective Effects and the Involved Mechanisms of Tanshinone IIA on Sepsis-Induced Brain Damage in Mice.
Guo, NZ; Wu, J; Xiong, CQ; Zhou, HC, 2019
)
1.48
"Tanshinone IIA (Tan IIA) has been reported to have neuroprotective effects to restrain the Aβ"( Tanshinone IIA Ameliorates Spatial Learning and Memory Deficits by Inhibiting the Activity of ERK and GSK-3β.
Ai-Hua, T; Jadoon, SS; Li, F; Lin, L; Liu, SZ; Wang, P; You, QY; Zhang, MY; Zhang, RY, 2019
)
2.68
"Tanshinone has been shown to affect osteoclast differentiation, but its role in osteoporosis remains less clear."( Tanshinone prevents alveolar bone loss in ovariectomized osteoporosis rats by up-regulating phosphoglycerate dehydrogenase.
Cheng, L; Wang, F; Wang, L; Wang, N; Zhang, B, 2019
)
2.68
"Tanshinone IIA (Tan IIA) has the properties of cardiovascular protection, anti-inflammation, antioxidation and anticancer. "( Characterization of the triplet state of tanshinone IIA and its reactivity by laser flash photolysis.
Li, K; Sun, X; Wang, M; Wang, SL; Wu, X; Zhang, Q; Zhu, R,
)
1.84
"Tanshinone IIA has definite protective effects on various cardiovascular diseases. "( The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy.
Han, B; Pang, H; Peng, Z; Yu, T, 2014
)
2.15
"Tanshinone IIA (TSA) has been reported to protect neurons and microvascular endothelial cells against ischemic injury. "( Tanshinone IIA dampens the cell proliferation induced by ischemic insult in rat astrocytes via blocking the activation of HIF-1α/SDF-1 signaling.
Feng, Y; Huang, X; Li, J; Li, Y; Xu, X, 2014
)
3.29
"Tanshinone IIA (TAN) has few clinical applications for anti-cancer therapy mainly due to its high lipophicity, low cellular uptake, and poor bioavailability. "( TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy.
Chen, M; Fang, X; Li, Y; Wang, Y; Zhang, J; Zhou, D, 2014
)
2.11
"Tanshinone IIA (TA) has been recently used to treat liver diseases. "( Enhanced hepatic targeting, biodistribution and antifibrotic efficacy of tanshinone IIA loaded globin nanoparticles.
Cao, X; Hu, Y; Li, J; Meng, L; Meng, Z; Wang, K; Wu, J, 2015
)
2.09
"Tanshinone IIA (Tan IIA) has been reported to exert anti-inflammatory effects in pulmonary fibrosis."( Tanshinone IIA ameliorates bleomycin-induced pulmonary fibrosis and inhibits transforming growth factor-beta-β-dependent epithelial to mesenchymal transition.
Gao, L; He, H; Ji, H; Lin, H; Liu, J; Mao, J; Tang, H; Wu, T, 2015
)
2.58
"Tanshinone IIA has been recently revealed to act directly on neutrophils."( Tanshinone IIA Protects against Dextran Sulfate Sodium- (DSS-) Induced Colitis in Mice by Modulation of Neutrophil Infiltration and Activation.
An, G; He, H; Huang, T; Lei, Z; Liu, F; Liu, X; Wen, T, 2016
)
2.6
"Tanshinone IIA has great potential as a candidate to protect host cells from H."( Inflammatory and Apoptotic Regulatory Activity of Tanshinone IIA in Helicobacter pylori-Infected Cells.
Chen, GY; Chuang, DY; Shu, YC; Wang, YC, 2016
)
1.41
"The tanshinone IIA has protective effects against the focal cerebral ischemic injury."( Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways.
Han, R; Tang, Q; Wang, G; Zhu, Y, 2017
)
2.38
"Tanshinone IIA (TSA) has been proven to protect the brain against focal ischemia injury."( The neuroprotective effects of Tanshinone IIA are associated with induced nuclear translocation of TORC1 and upregulated expression of TORC1, pCREB and BDNF in the acute stage of ischemic stroke.
Cui, L; Du, W; Li, M; Liu, L; Wang, L; Wang, S; Yang, R; Zhang, X, 2010
)
1.37
"Tanshinone IIA (Tan IIA) has been reported many times for the treatment of MI."( Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXC chemokine receptor 4 axis in a myocardial ischemia model.
Chen, Y; Han, H; Hong, D; Qiao, H; Tong, Y; Wu, Y; Xu, W; Yang, J; Zhou, C, 2011
)
2.53
"Tanshinone IIA has been confirmed to suppress miR-1 and reduce the arrhythmogenesis after myocardial infarction (MI)."( Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes.
Chu, W; Li, B; Li, X; Lu, Y; Shan, H; Wang, B; Yang, B; Zhang, J; Zhang, L; Zhang, Y; Zhao, M, 2010
)
2.52
"Tanshinone I has a good absorbing in the rat small intestine."( [Absorption mechanism of tanshinone II A, cryptotanshinone, tanshinone I and tanshinones extract in rat small intestine in vivo].
Du, S; Li, X; Wu, Q; Yan, H; Yang, Y; Zhou, L, 2010
)
1.39
"Tanshinone IIA (Tan IIA) has been reported for neuroprotective potential to against amyloid β peptides (Aβ)-induced cytotoxicity in the rat pheochromocytoma cell line PC-12, which is widely used as AD research model, but the mechanism still remains unclear."( Tanshinone IIA protects PC12 cells from β-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway.
Dong, H; Liu, B; Mao, S; Wei, J; Yan, M; Zhang, Q; Zhang, Z, 2012
)
2.54
"Tanshinone II A has better anti-leukemia effects on SUP-B15, K562, CEM, NB4 than on HL-60."( [Anti-tumor effect of tanshinone II A, tetrandrine, honokiol, curcumin, oridonin and paeonol on leukemia cell lines].
Gong, YP; Guo, Y; Lin, J; Shan, QQ; Yang, X; Zhou, RQ, 2012
)
1.41
"Tanshinones have been identified as a novel class of Nrf2-inducers for antioxidant tissue protection in an in vivo As(III) inhalation model, that is relevant to low doses of environmental exposure."( Tanshinone I activates the Nrf2-dependent antioxidant response and protects against As(III)-induced lung inflammation in vitro and in vivo.
Chau, BT; Jaramillo, MC; Lantz, RC; Lau, A; Tao, S; Wondrak, GT; Wong, PK; Zhang, DD; Zheng, Y, 2013
)
3.28
"Tanshinone II A has an inhibitive effect on the proliferation of K562 cells and an inductive effect on the differentiation of erythrocyte series. "( [Study on the differentiation of K562 cell-line induced by Tanshinone II A].
Jia, Y; Li, Y; Liu, T; Meng, W; Wu, Y; Yang, Y, 2002
)
2

Actions

Tanshinone IIA may increase AFV in normal pregnancy by downregulating AQP1 protein expression in the fetal membranes, which may be associated with p-GSK-3β signaling pathway. Tanshinones IIA can inhibit Ang II-induced proliferation and autophagy of VSMCs via regulating the MAPK signaling pathway.. Tanshinone II A promotes KLF4 expression during smooth muscle phenotypic switching.

ExcerptReferenceRelevance
"Tanshinone IIA may inhibit GC tumor growth via affecting the intestinal microbiome through regulating the NF-"( Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome.
Lu, F; Shen, N; Song, P; Wang, Q; Wu, Z; Xu, Y; Zhang, Y, 2022
)
3.61
"Tanshinone IIA may increase AFV in normal pregnancy by downregulating AQP1 protein expression in the fetal membranes, which may be associated with p-GSK-3β signaling pathway. "( Tanshinone IIA changed the amniotic fluid volume and regulated expression of AQP1 and AQP3 in amniotic epithelium cells: a promising drug treating abnormal amniotic fluid volume.
Chen, B; Hua, Y; Lan, Y; Pan, S; Ying, X; Zhou, Y, 2023
)
3.8
"Tanshinone IIA can inhibit Ang II-induced proliferation and autophagy of VSMCs via regulating the MAPK signaling pathway."( Tanshinone IIA Can Inhibit Angiotensin II-Induced Proliferation and Autophagy of Vascular Smooth Muscle Cells via Regulating the MAPK Signaling Pathway.
Ding, Y; Liu, N; Lu, J; Shan, J; Wang, P, 2019
)
2.68
"Tanshinone II A promotes KLF4 expression during smooth muscle phenotypic switching."( Tanshinone II A attenuates vascular remodeling through klf4 mediated smooth muscle cell phenotypic switching.
Chen, X; Gong, D; Hu, W; Huang, Q; Lou, G; Shi, Y; Wang, B; Wang, Y; Wen, L; Wu, Z; Xu, H; Xu, Y; Yang, L; Yao, H, 2020
)
2.72
"Tanshinone IIA could inhibit LPS-induced inflammation and cell apoptosis of chondrocytes via regulating the expression of miR-155 and FOXO3."( Tanshinone IIA Ameliorates Inflammation Response in Osteoarthritis via Inhibition of miR-155/FOXO3 Axis.
Guo, YX; Li, LH; Li, WY; Liu, D; Lu, XL; Luo, WB; Tan, LM; Tang, Z; Xiong, H; Zhou, B; Zhu, LG, 2021
)
2.79
"Tanshinone I also caused increase the ROS levels in these cells which was linked with the reduction the MMP levels."( Tanshinone l exhibits anticancer effects in human endometrial carcinoma HEC-1-A cells via mitochondrial mediated apoptosis, cell cycle arrest and inhibition of JAK/STAT signalling pathway.
Cao, Q; Hou, X; Li, Q; Liang, Y; Ma, X; Mu, W; Zhang, J,
)
2.3
"Tanshinone I could also inhibit LPS-induced NF-κB activation in microglia."( Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Chai, L; Guo, H; Hu, L; Jing, H; Liu, Z; Wang, S; Yang, H, 2015
)
2.58
"Tanshinone IIA (Tan IIA) promotes fibrinolysis in hepatic fibrosis and the cardiovascular system and may play a role in preventing adhesions."( Efficacy and mechanism of tanshinone IIA liquid nanoparticles in preventing experimental postoperative peritoneal adhesions in vivo and in vitro.
Hou, C; Hou, L; Li, X; Lin, S; Ma, Y; Qin, F; Wang, C; Wang, X; Wei, Y, 2015
)
1.44
"Tanshinone II A can inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma cell line SMMC-7721, which may be related to the down-regulation of EGF and EGFR protein expression."( [Effect of Tanshinone II A on expression of EGF and EGFR in hepatocellular carcinoma cell line SMMC-7721].
Chen, JH; Han, M; He, SX; Hou, HL; Ren, MD; Wang, ZL; Zhai, XM, 2009
)
2.19
"Tanshinones could inhibit the proliferation of SPC-A-1 cells effectively, and their cytotoxicities on SPC-A-1 cells are all in concentration-dependent and time-dependent manners. "( [Growth inhibition of tanshinones on SPC-A-1 cell line and their structure-activity relationship].
Chu, T; Jin, H; Li, H; Mao, S; Shi, H; Zhang, Q, 2011
)
2.13
"Tanshinone IIA did not inhibit growth of single-xenotransplanted tumors, but it did reduce the occurrence of metastases."( Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization.
Chai, ZT; Fu, YL; Kong, LQ; Liu, L; Lu, L; Ren, ZG; Sun, HC; Tang, ZY; Wang, WQ; Xu, HX; Zhang, QB; Zhu, XD, 2012
)
2.54
"Tanshinone could increase the number of life cells and decrease LDH activity significantly, particularly in hypoxia and caffeine injured model."( [Protective effect of tanshinone on injured cultured PC12 cells in vitro].
He, LN; He, SB; Jiang, Y; Liu, C; Wang, J; Yang, J, 2001
)
1.35
"Tanshinone IIA can inhibit the growth of human hepatoma BEL-7402 cells possibly through the mechanism of apoptosis induction."( [Effect of tanshinone IIA on the growth behavior of human hepatoma cell line BEL-7402 in vitro and its mechanism].
Fu, LB; Tang, Y; Tang, ZZ, 2003
)
2.15
"Tanshinone II-A could inhibit the growth and proliferation of HCC cell effectively in vitro by apoptosis induction, which was associated with up-regulation of fas, p53, bax, expression and down-regulation of bcl-2 and c-myc."( Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells.
Li, SF; Wang, XJ; Wei, YQ; Xiao, F; Yuan, SL; Zhang, J, 2004
)
2.03
"Tanshinone IIA can inhibit the proliferation of NCI-H460 and induce the apoptosis of the cell."( [Inhibition of proliferation and induction of apoptosis by tanshinone II A in NCI-H460 cell].
Deng, H; Hu, H; Huang, F; Zhang, Y, 2005
)
2.01
"Tanshinone II A suppress stack of extracellular matrix after balloon injury so as to prevent restenosis."( [Inhibitive effect to collagen fiber of tanshinone II A in iliac artery following balloon injury in rabbit].
Chen, H; Chen, Y; Liang, Y; Long, B; Zeng, Z, 2005
)
2.04
"Tanshinone IIA can inhibit the proliferation of human hepatoma cell line HepG2 in a time- and dose- dependent manner, and the mechanism of growth inhibition of human hepatoma cells may be related to the induction of apoptosis."( [Inhibition of cell growth and induction of apoptosis in human hepatoma cell line HepG2 by tanshione IIA].
Chen, WG; Li, QX; Liu, YH; Qiu, Y; Zhong, ZH, 2007
)
1.78
"Tanshinone II A could inhibit the negative effect of Ang- II on NO production and eNOS expression in PAEC."( [Effect of tanshinone II A on angiotensin II induced nitric oxide production and endothelial nitric oxide synthase gene expression in cultured porcine aortic endothelial cells].
Li, YS; Liang, QS; Wang, J, 2007
)
2.17

Treatment

Tanshinone IIA treatment at a dose of 0.5 mg/kg significantly inhibited cartilage degradation and improved Mankin scores in the OA rat model (P<0.002). Tanshin one IIA treatment induced significant apoptosis in TOV-21G cells. Tanshinone IIA enhances the therapeutic effects of BMSC transplant on SCI.

ExcerptReferenceRelevance
"Tanshinone II A treatment significant inhibits rat smooth muscle cell proliferation and migration."( Tanshinone II A attenuates vascular remodeling through klf4 mediated smooth muscle cell phenotypic switching.
Chen, X; Gong, D; Hu, W; Huang, Q; Lou, G; Shi, Y; Wang, B; Wang, Y; Wen, L; Wu, Z; Xu, H; Xu, Y; Yang, L; Yao, H, 2020
)
2.72
"Tanshinone IIA treatment at a dose of 0.5 mg/kg significantly inhibited cartilage degradation and improved Mankin scores in the OA rat model (P<0.002)."( Articular cartilage degradation is prevented by tanshinone IIA through inhibiting apoptosis and the expression of inflammatory cytokines.
Jia, PT; Li, L; Lu, X; Zhang, XL; Zuo, HN, 2017
)
1.43
"Tanshinone IIA treatment induced significant apoptosis in TOV-21G cells. "( Tanshinone IIA effects on ovarian cancer cell line.
Chen, S; Li, N; Yang, L; Zhang, B, 2018
)
3.37
"Tanshinone IIA treatment enhances the therapeutic effects of BMSC transplant on SCI, likely by promoting the differentiation of neuronal cells."( Tanshinone IIA promotes the differentiation of bone marrow mesenchymal stem cells into neuronal-like cells in a spinal cord injury model.
Fu, J; Jiao, ZM; Li, JY; Ma, J; Sun, Y; Wang, D; Yu, BQ; Yu, MY; Zhang, XM, 2018
)
3.37
"Tanshinone IIA treatment increased the irradiation sensitivity of laryngeal cancer cells by reducing cell survival, viability and proliferation, and increasing cell apoptosis."( Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway.
Chen, L; Hao, YL; Xu, FW; Xu, H; Xu, LN, 2018
)
2.64
"Tanshinone IIA treatments (13.6-54.4[Formula: see text][Formula: see text]M) significantly decreased nuclear factor kappa B (NF-kB) and mitogen-activated protein kinase (MAPK) [p-38 and C-terminal Jun-kinase 1/2 (JNK1/2)] protein expressions and inflammatory substance [cyclooxygenase-2 (COX-2), 5-lipooxygenase (5-LOX), intercellular adhesion molecule-1 (ICAM-1), reactive oxygen species (ROS), nitric oxide (NO), inducible nitric oxide synthase (iNOS), interleukin-1[Formula: see text] (IL-1[Formula: see text], IL-6, and IL-8] production in the H."( Inflammatory and Apoptotic Regulatory Activity of Tanshinone IIA in Helicobacter pylori-Infected Cells.
Chen, GY; Chuang, DY; Shu, YC; Wang, YC, 2016
)
1.41
"Tanshinone IIA pretreatment resulted in a significant reduction of cerebral infarct volume in MCAO rats. "( Tanshinone IIA prevented brain iron dyshomeostasis in cerebral ischemic rats.
Bi, Z; Cai, B; Lu, Y; Shan, H; Yang, L; Yin, L; Zhang, B; Zhang, L, 2011
)
3.25
"Treatment with tanshinone IIA can improve MCT-induced pulmonary hypertension in rats through the PI3K/Akt-eNOS signaling pathway."( [Tanshinone IIA alleviates monocrotaline-induced pulmonary hypertension in rats through the PI3K/Akt-eNOS signaling pathway].
Li, G; Liu, S; Sun, Y; Zhang, X, 2022
)
1.98
"Treatment of tanshinone II A significantly up-regulated the expression of GSDMD and miR-145."( Tanshinone II A enhances pyroptosis and represses cell proliferation of HeLa cells by regulating miR-145/GSDMD signaling pathway.
Guo, J; Tong, W; Yang, C, 2020
)
2.35
"Treatment with tanshinone I decreased these levels and lowered blood glucose level in T2DM rats."( Tanshinone I alleviates insulin resistance in type 2 diabetes mellitus rats through IRS-1 pathway.
Gao, J; Liu, T; Qin, L; Shi, H; Wang, D; Wei, Y; Xu, T; Xu, Y, 2017
)
2.24
"Treatment with tanshinone IIA effectively inhibited spastic cerebral palsy, and the activities of interleukin (IL)‑1β, IL‑6, tumor necrosis factor‑α, monocyte chemoattractant protein 1, cyclooxygenase‑2 and prostaglandin E2 in a neonatal rat model of SCP."( Neuroprotective effect of tanshinone IIA weakens spastic cerebral palsy through inflammation, p38MAPK and VEGF in neonatal rats.
Cao, YA; Peng, CS; Tian, L; Xia, J; Yang, L; Zhang, WL, 2018
)
1.12
"Rats treated with tanshinone experienced more stable heart rate after ischemia-reperfusion compared with those in the saline control group. "( Tanshinone modulates the expression of Bcl-2 and Bax in cardiomyocytes and has a protective effect in a rat model of myocardial ischemia-reperfusion.
Guo, R; Li, G,
)
1.91
"Treatment with tanshinone IIA-NP improved cardiac function, limited infarct expansion, and prevented left ventricle dilation at 4 weeks post-MI."( Nanoparticle-mediated delivery of Tanshinone IIA reduces adverse cardiac remodeling following myocardial infarctions in a mice model: role of NF-κB pathway.
Chen, P; Guo, R; Lan, Y; Mao, S; Wang, L; Zhang, M, 2018
)
1.1
"The treatment with tanshinone II(A) could inhibit left ventricle hypertrophy of renal hypertensive rats. "( [Effect of tanshinone II(A) on expression of different components in renin-angiotensin system of left ventricles of hypertensive rats].
Shi, CR; Yu, LZ, 2014
)
1.12
"Treatment with Tanshinone IIA prevented degeneration of nigrostriatal DA neurons and increased the level of striatal dopamine content."( Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
Ren, B; Si, DW; Sun, FW; Wei, Z; Zhang, CY; Zhang, YX; Zhang, ZF; Zhou, HX, 2015
)
2.2
"Pretreatment with tanshinone I significantly reduced adhesion of either monocyte U937 or MDA-MB-231 cells to HUVECs."( Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules.
Chang, KC; Cho, MK; Jeon, SJ; Kang, SS; Kim, HJ; Kim, YS; Lee, GW; Lee, JH; Lee, JS; Nizamutdinova, IT; Seo, HG; Son, KH, 2008
)
2.11
"The treatment with tanshinone IIa could significantly decrease the serum levels of IL-1beta, TNF-alpha and platelet number, and the efficacy of tanshinone IIa was same as aspirin."( [Effects of Tanshinone IIa on cytokines and platelets in immune vasculitis and its mechanism].
Li, XH; Li, XJ; Liu, H; Xu, YH; Yang, M; Zhou, M, 2009
)
1.05
"Treatment with tanshinone IIA prevented increased SRF and hence increased miR-1 post-MI, whereas quinidine did not."( Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1.
Cai, B; Chu, W; Li, B; Li, X; Lu, Y; Pan, Z; Qiao, G; Shan, H; Xu, C; Yang, B; Zhang, L; Zhang, Y, 2009
)
2.14
"Upon treatment with tanshinone IIA, breast cancer cell proliferation was significantly inhibited in a dose- and time-dependent manner (IC50 = 0.25 microg/ml) and apoptotic cell populations increased, while tamoxifen inhibited only ER-positive breast cancer cells prominently and had no effect on ER-negative cells."( Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer.
Chen, J; Lu, Q; Zhang, P; Zhang, X, 2009
)
0.92
"Treatment with tanshinone II-A had inhibitory effects on the migration and invasion of HCC cells. "( Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo.
Feng, T; Ren, L; Yuxian, X; Zhengcai, L,
)
1.93
"MSCs treated with tanshinone IIA and astragaloside IV showed stronger migration than that of the control."( Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4.
Chen, J; Li, F; Ma, J; Nan, Y; Song, T; Wang, H; Wang, W; Wang, Z; Xie, J; Yi, H, 2013
)
2.16
"Treatment with TanshinoneIIA prevented increased PU.1 and hence increased miR-155, whereas aspirin could not."( TanshinoneIIA ameliorates inflammatory microenvironment of colon cancer cells via repression of microRNA-155.
Guo, L; Guo, Y; Tang, F; Tu, J; Xi, T; Xing, Y, 2012
)
2.16
"Oral treatment of tanshinone IIA caused a dose-dependent increase of liver microsomal 7-methoxyresorufin O-demethylation (MROD) activity in B6 but not in D2 mice."( Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice.
Chen, CF; Kuo, YH; Lin, YL; Ueng, YF; Wang, SY, 2004
)
0.91
"Treatment with tanshinone IIA significantly reduced the severity of brain injury, as indicated by the increase in ipsilateral brain weight and neuron density, compared with those of sham-operated animals."( Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage.
Chan, WY; Chik, KW; Fok, TF; Fung, KP; Gu, GJ; Li, K; Ng, HK; Ng, PC; Wang, CC; Woo, KS; Xia, WJ; Yang, M, 2005
)
0.92

Toxicity

ExcerptReferenceRelevance
" However, its clinical use is limited due to the side effect of cardiotoxicity."( Tanshinone I inhibits doxorubicin-induced cardiotoxicity by regulating Nrf2 signaling pathway.
Chen, X; Guo, D; Hong, Y; Jiang, Q; Jiang, Y; Li, C; Liu, T; Sun, Q; Tian, X; Wang, Q; Wang, X; Wang, Y; Xue, S; Zhang, J, 2022
)
2.16

Pharmacokinetics

A fast, sensitive and reliable ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed and validated for simultaneous quantitation and pharmacokinetic study of five tanshinones.

ExcerptReferenceRelevance
" The results of pharmacokinetic studies in rabbits indicated that the formulation of TA-SLN was successful in providing a delivery of slow release of Tashinone IIA."( Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles.
Du, Z; Liu, J; Qin, B; Zhu, J, 2005
)
0.33
" Its pharmacokinetic characteristics, absolute bioavailability, tissue distribution and plasma protein binding properties were determined."( Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion.
Cui, N; Ding, Z; Hao, H; Li, J; Wang, G; Xie, L, 2006
)
0.58
" The established method has been successfully applied in the pharmacokinetic study and drug interaction of danshensu, ferulic acid, cryptotanshinone, and tanshinone IIA in rabbits after intravenous administration of danxiongfang, a useful compound preparation of traditional Chinese medicine."( Simultaneous determination of danshensu, ferulic acid, cryptotanshinone and tanshinone IIA in rabbit plasma by HPLC and their pharmacokinetic application in danxiongfang.
Li, X; Li, Y; Wang, L; Xu, Y; Xue, M, 2007
)
0.78
" This is the first report on the determination and pharmacokinetic study of danshensu, salvianolic acid B and tanshinone IIA in rat plasma and the results indicated that this method was reliable for the determination of the major active components of danshen in rat plasma."( Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method.
Chen, Q; Deng, L; Fu, H; Gong, T; Liu, J; Nie, Y; Wang, X; Zhang, ZR, 2007
)
0.55
" This method was successfully applied to the pharmacokinetic study of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone after oral administration of PF2401-SF, the standardized fraction of Salvia miltiorrhiza enriched with tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone to male Sprague-Dawley rats."( Simultaneous determination of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study of a standardized fraction of Salvia miltiorrhiza,
Ji, HY; Kim, NJ; Kim, YC; Kim, YH; Lee, HS; Park, EJ; Sohn, DH; Song, WY, 2008
)
0.87
" The in vivo clearance of tanshinone IIA was acquired from a pharmacokinetic study in rat."( The prediction of the hepatic clearance of tanshinone IIA in rat liver subcellular fractions: accuracy improvement.
Khlentzos, A; Li, J; Li, P; Liu, X; Roberts, MS; Wang, GJ; Zhang, Q, 2008
)
0.91
" To identify suitable pharmacokinetic (PK) marker(s) for indicating systemic exposure to cardiotonic pills, we examined the in vivo PK properties of putatively active phenolic acids from the component herb Danshen (Radix Salviae miltiorrhizae)."( Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine.
Chen, P; Du, F; Gao, X; Huang, Y; Li, C; Liu, C; Lu, T; Shang, H; Sun, Y; Wan, R; Wang, F; Wang, Y; Xu, F; Yang, J; Zhang, B, 2008
)
0.35
"To investigate the synergistic effect of salvianolic acids (Sals) and tanshinones (Tans), to compare the pharmacodynamic effect of Danshen co-microemulsion, salvianolic acids microemulsion, tanshinones microemulsion, tanshinones suspension and blank microemulsion on hemorheology in rats with hyperlipidemia."( [Comparative research on pharmacodynamics of Danshen co-microemulsion on hemorheology in rats with hyperlipidemia].
Ji, HS; Yang, J; Yu, F, 2008
)
0.58
" However, no significant differences in the terminal elimination half-life (t(1/2)) of TSIIA and Sal B in the mixed extracts-loaded emulsion groups were found compared with that of the corresponding extract groups except for the high dose groups of TSIIA (p<0."( Pharmacokinetic interaction between tanshinones and polyphenolic extracts of salvia miltinorrhiza BUNGE after intravenous administration in rats.
Guo, ZJ; Li, H; Sun, QS; Tang, X; Zhang, Y, 2008
)
0.62
"This paper describes a rapid and sensitive high-performance liquid chromatographic (HPLC) method for the determination of the concentration of tanshinone I in rat plasma, and applies the method to pharmacokinetic study."( Determination of tanshinone I in rat plasma by high-performance liquid chromatography and its application to pharmacokinetic studies.
Du, W; Qin, HY; Wei, YH; Wu, XA; Zhao, G, 2008
)
0.89
" This method has been successfully applied in the simultaneous quantification and the pharmacokinetic studies of these six compounds in animals which were orally administered with danshen preparations."( Simultaneous determination of danshensu, rosmarinic acid, cryptotanshinone, tanshinone IIA, tanshinone I and dihydrotanshinone I by liquid chromatographic-mass spectrometry and the application to pharmacokinetics in rats.
Li, X; Li, Y; Liu, Y; Wang, L; Xue, M, 2010
)
0.6
" The pharmacokinetic behavior of the incorporated drug can be modified by changing the surface characteristics of SLNs with the use of poloxamer 188."( Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats.
Chen, ZQ; Liu, JP; Liu, XX; Zhang, WL, 2009
)
0.79
" The pharmacokinetic parameters of TS-PLA-NP and tashinone II(A) injection were calculated by program DAS2."( [Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit].
Chen, HY; Fan, ZZ; Feng, NP; Li, Q; Nan, YL; Wang, Y; Zhong, LH, 2011
)
0.37
"The method for the pharmacokinetic research of tshinone II A in rabbit plasma is accuracy, rapid and sensitive."( [Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit].
Chen, HY; Fan, ZZ; Feng, NP; Li, Q; Nan, YL; Wang, Y; Zhong, LH, 2011
)
0.37
" Pharmacokinetic studies manifested that both TA-d-rHDL and TA-s-rHDL markedly improved pharmacokinetic behaviors of TA in vivo."( Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins.
He, H; Liu, J; Wang, J; Wu, Z; Zhang, S; Zhang, W, 2013
)
0.63
"To establish a LC-MS/MS method for determining the concentration of tanshinone IIA, salvianolic acid B and paeoniflorin of refined coronary cataplasm in rabbit plasma, in order to determine the concentration of the three main ingredients in blood after transdermal administration and calculate their pharmacokinetic parameters."( [Pharmacokinetic study on three main ingredients of refined coronary cataplasm].
Du, MB; Hou, R; Liang, RX; Liu, SZ; Wang, L; Wang, YL; Zhang, JY, 2012
)
0.61
" Winnonlin software was used to calculate their major pharmacokinetic parameters."( [Pharmacokinetic study on three main ingredients of refined coronary cataplasm].
Du, MB; Hou, R; Liang, RX; Liu, SZ; Wang, L; Wang, YL; Zhang, JY, 2012
)
0.38
" After transdermal administration of refined coronary cataplasm in rabbits, the main pharmacokinetic parameters of tanshinone IIA, salvianolic acid B or paeoniflorin were as follows: Cmax (20."( [Pharmacokinetic study on three main ingredients of refined coronary cataplasm].
Du, MB; Hou, R; Liang, RX; Liu, SZ; Wang, L; Wang, YL; Zhang, JY, 2012
)
0.59
" The pharmacokinetic characteristics of tanshinone IIA, salvianolic acid B and paeoniflorin are suitable to assess the percutaneous absorption of refined coronary cataplasm."( [Pharmacokinetic study on three main ingredients of refined coronary cataplasm].
Du, MB; Hou, R; Liang, RX; Liu, SZ; Wang, L; Wang, YL; Zhang, JY, 2012
)
0.65
" The rapid and sensitive method was fully validated and successfully applied to the pharmacokinetic study of formononetin, cryptotanshinone, tanshinone IIA and emodin in rats following oral administration of Bu Shen Huo Xue formula."( A rapid UFLC-MS/MS method for simultaneous determination of formononetin, cryptotanshinone, tanshinone IIA and emodin in rat plasma and its application to a pharmacokinetic study of Bu Shen Huo Xue formula.
Huang, K; Pan, Y; Ren, Y; Wang, X; Xiang, Z; Xu, Y; Yan, P, 2013
)
0.82
" Pharmacokinetic parameters were estimated using non-compartmental methods."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" The values of Cmax and AUC(0-t) after IT were significantly higher than IV."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" Co-administration of Danshen and Sanqi could cause significant pharmacokinetic herb-herb interactions in guinea pigs."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
"A reliable high-performance liquid chromatography method was adopted for simultaneous determination of lithospermic acid B and tanshinone II A in rat plasma, through which the pharmacokinetic interaction between lithospermic acid B and tanshinone II A by intravenous injection was investigated."( Pharmacokinetic investigation on interaction between hydrophilic lithospermic acid B and lipophilic tanshinone IIA in rats: an experi- mental study.
Mao, S; Wei, G; Xiuli, W, 2015
)
0.84
"The simultaneous intravenous injection of tanshinone II A and lithospermic acid B significantly altered the pharmacokinetic parameters of both compounds when compared with the individual intravenous administration of each compound."( Pharmacokinetic investigation on interaction between hydrophilic lithospermic acid B and lipophilic tanshinone IIA in rats: an experi- mental study.
Mao, S; Wei, G; Xiuli, W, 2015
)
0.9
" Pharmacokinetic studies of these optimized TA-SRPs validated that their actual plasma concentration-time curve possessed a basically consistent trend with the predicted plasma concentration-time curve and the absolute percent errors (%PE) of concentrations in 8-12h were less than 10%."( Tanshinone IIA - loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation.
Li, J; Li, ZH; Liu, JP; Yan, HX; Zhang, WL, 2015
)
1.86
"The aim of this study was to investigate the pharmacokinetic interaction between tanshinones and polyphenolics which act as the main bioactive compounds in Saliva miltiorrhiza Bunge (SMB)."( Simultaneous determination of tanshinones and polyphenolics in rat plasma by UPLC-MS/MS and its application to the pharmacokinetic interaction between them.
Duan, J; Guan, H; Qian, D; Ren, H; Shang, E; Su, S; Zhang, W, 2016
)
0.95
" Male Sprague-Dawley rats were randomly assigned to 3 groups: LST, LST+SA-B and LST+Tan IIA, and the main pharmacokinetic parameters were estimated after oral administration of LST, LST+SA-B and LST+Tan IIA."( Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
Wang, R; Wang, Y; Yu, X; Yuan, Y; Zhang, H, 2016
)
0.71
"A fast, sensitive and reliable ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed and validated for simultaneous quantitation and pharmacokinetic study of five tanshinones (tanshinone I, tanshinone IIA, tanshinone IIB, dihydrotanshinone I, cryptotanshinone), the bio-active ingredients of Huo Luo Xiao Ling Dan (HLXLD) in rat plasma."( Pharmacokinetic comparison of five tanshinones in normal and arthritic rats after oral administration of Huo Luo Xiao Ling Dan or its single herb extract by UPLC-MS/MS.
Bian, Q; Dai, R; Lee, DY; Ma, W; Peng, Y; Wang, N; Wang, W, 2016
)
0.9
" The plasma concentrations of tanshinones were detected by a validated method and pharmacokinetic parameters were calculated using a non-compartmental model."( Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers.
Cheng, JL; Deng, W; Huang, WH; Tan, ZR; Xing, L; Yuan, CS; Zhang, W; Zhou, HH, 2017
)
1
" The quantitative retention-activity relationships (QRARs) of the constituents were established to model their pharmacokinetic (PK) parameters and chromatographic retention data, and generate their biological effectiveness fingerprints."( Determination of quantitative retention-activity relationships between pharmacokinetic parameters and biological effectiveness fingerprints of Salvia miltiorrhiza constituents using biopartitioning and microemulsion high-performance liquid chromatography.
Gao, H; Huang, H; Li, N; Yu, N; Zheng, A, 2017
)
0.46
" A sequential, open-label, and two-period pharmacokinetic drug interaction study was designed to compare clopidogrel pharmacokinetic parameters before and after 7 days of administration of Danshen capsules in twenty healthy male volunteers."( Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Xu, M; Yu, HB; Zhang, LT; Zheng, XT; Zhong, ZF; Zhou, CH, 2018
)
0.48
" All of the analytes displayed significant higher area under the concentration-time curve and peak concentration after oral administration of UGP than after TDS, indicating that ultrafine powder product could improve the bioavailability and absorption of cryptotanshinon,tanshinone II A,dihydrotanshinonE I and tanshinone I in vivo."( Comparative in vivo constituents and pharmacokinetic study in rats after oral administration of ultrafine granular powder and traditional decoction slices of Chinese Salvia.
Cheng, J; Deng, W; Deng, Y; Guo, D; Hou, J; Li, Z; Qi, P; Wu, W; Zhi, H, 2019
)
0.69
"The prolongation of the coexistence of the four active components in Danshen in vivo by regulating their pharmacokinetic processes may contribute to better efficiency."( Development of sustained-release pellets to modulate the in vivo processes of the main active components of Danshen: A pharmacokinetic and pharmacodynamic evaluation.
Jiang, C; Liu, J; Tang, H; Wang, B; Wang, D; Zhang, S, 2019
)
0.51
" The four kinds of sustained-release pellets were filled into capsules on the basis of the original weight ratio of the four active components in purified Salvia miltiorrhiza extract for further in vitro release and pharmacokinetic and pharmacodynamic investigations."( Development of sustained-release pellets to modulate the in vivo processes of the main active components of Danshen: A pharmacokinetic and pharmacodynamic evaluation.
Jiang, C; Liu, J; Tang, H; Wang, B; Wang, D; Zhang, S, 2019
)
0.51
" To investigate the pharmacokinetic interaction between FDDP and CBT after oral administration of FDDP, CBT and their combination in rats, a novel LC-MS method with segmented scan modes (multiple reaction monitoring and selected ion monitoring) and polarity (positive and negative ionization) was developed."( Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between Fufang Danshen Dripping Pill and Clopidogrel Bisulfate Tablet.
Du, Y; Guo, MZ; Ji, L; Ji, S; Ma, YS; Shao, X; Su, ZY; Tang, DQ; Wang, YJ; Zhao, L, 2019
)
0.51
"2% to 112%, which demonstrated that the LC-MS/MS method could be used to evaluate the pharmacokinetic feature of the six compounds in rats after oral administration of DLT."( A network pharmacology integrated pharmacokinetics strategy for uncovering pharmacological mechanism of compounds absorbed into the blood of Dan-Lou tablet on coronary heart disease.
Chang, YX; Chen, S; Ding, M; Gao, XM; Li, J; Li, Y; Ma, W; Mao, H; Wang, H; Wang, Q; Wang, X; Wei, J; Yang, X; Yang, Y; Zou, S, 2019
)
0.51
" Plasma concentrations of warfarin enantiomers were determined by UPLC-MS/MS method, pharmacokinetic parameters were calculated."( Effects of sulfotanshinone sodium injection on the pharmacokinetics and pharmacodynamics of warfarin in rats
Chen, J; Dong, M; Huang, L; Jiang, M; Liu, D; Liu, G; Shi, Y; Zhang, W; Zhou, Y, 2020
)
0.9
" The differences in the pharmacokinetic and tissue distribution behaviors of the four tanshinones after oral administration of the liposoluble extract of Salvia miltiorrhiza and pure compounds are not clear."( Comparative pharmacokinetics and tissue distribution of cryptotanshinone, tanshinone IIA, dihydrotanshinone I, and tanshinone I after oral administration of pure tanshinones and liposoluble extract of Salvia miltiorrhiza to rats.
Cao, L; Huang, M; Jin, J; Tan, G; Wang, D; Xu, C; Yu, W; Zhao, Z, 2020
)
1.02
" In comparison with Danshen and Sanqi alone, there were significant differences in pharmacokinetic parameters of TS IIA, SAB and Rg1, and the brain distribution of SAB and TS IIA when Danshen, Sanqi and borneol were administrated together."( The effects of borneol on the pharmacokinetics and brain distribution of tanshinone IIA, salvianolic acid B and ginsenoside Rg
Jia, LJ; Li, JP; Liu, SL; Shi, LY; Wang, H; Xie, BP; Zhang, J, 2021
)
0.85

Compound-Compound Interactions

Alprostadil combined with tanshinone IIa injection can effectively improve microcirculation and ventricular remodeling, improve cardiac function and reduce the occurrence of MACEs. When Tanshin one was combined with cisplatin at a ratio of 20:1, they were observed to exert a synergistic inhibitory effect on non-small-cell lung cancer cells.

ExcerptReferenceRelevance
"There were apoptosis synergism on MR2 cell induced by Tan II A combined with As2O3, at the same time reduced the expression of Pgp in the cells."( [Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide].
Li, L; Zhang, ZH; Zhao, WD, 2009
)
0.63
"To evaluate the synergistic effects of Tanshinone II A (Tan II A) combined with arsenic trioxide (ATO) on apoptosis and differentiation of NB4 cells."( [Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Meng, WT; Yang, YM; Zhang, G; Zhou, J, 2010
)
0.91
"The NB4 cells were treated with Tan II A, ATO, and Tan II A combined with ATO, respectively."( [Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Meng, WT; Yang, YM; Zhang, G; Zhou, J, 2010
)
0.64
"To evaluate the therapeutic effect of clarithromycin combined with tanshinone in the treatment of rhinosinusal and laryngeal radiation injury induced by radiotherapy in patients with nasopharyngeal carcinoma (NPC)."( [Clarithromycin combined with tanshinone for rhinosinusal and laryngeal radiation injury in patients with nasopharyngeal carcinoma after radiotherapy].
Li, H; Ma, Y; Wang, H; Zhao, J, 2012
)
0.9
"Clarithromycin combined with tanshinone can be an effective regimen for treatment of rhinosinusal and laryngeal radiation injury induced by radiotherapy in NPC patients."( [Clarithromycin combined with tanshinone for rhinosinusal and laryngeal radiation injury in patients with nasopharyngeal carcinoma after radiotherapy].
Li, H; Ma, Y; Wang, H; Zhao, J, 2012
)
0.96
" In this report, the results demonstrated that the tanshinone II A, a key component of Salvia miltiorrhiza bunge, when it is combined with the cytotoxic drug cisplatin showed synergistic antitumor effects on human prostate cancer PC3 cells and LNCaP cells in vitro."( [Synergistic antitumor effects of tanshinone II A in combination with cisplatin via apoptosis in the prostate cancer cells].
Hou, LL; Hu, GQ; Xie, SQ; Xu, QJ, 2013
)
0.92
"To assess the effects of TSII-A or CPT combined with albendazole on optic neuritis due to the infection, mice were divided into six groups, including the normal control group, infection group and four treatment groups (albendazole group, albendazole combined with dexamethasone group, albendazole combined with CPT group and albendazole combined with TSII-A group)."( Effects of albendazole combined with TSII-A (a Chinese herb compound) on optic neuritis caused by Angiostrongylus cantonensis in BALB/c mice.
Feng, F; Feng, Y; Li, WH; Liu, Z; Lv, Z; Wang, WC; Wu, ZD, 2015
)
0.42
" In treatment groups, albendazole could not alleviate the above symptoms; albendazole combined with dexamethasone lessened the inflammation of the retina, but was futile for the other changes; however, albendazole combined with CPT and albendazole combined with TSII-A showed obvious effects on the recovery of prolonged VEP latency, destruction and reduction of ganglion cells, optic nerve demyelination and axon loss."( Effects of albendazole combined with TSII-A (a Chinese herb compound) on optic neuritis caused by Angiostrongylus cantonensis in BALB/c mice.
Feng, F; Feng, Y; Li, WH; Liu, Z; Lv, Z; Wang, WC; Wu, ZD, 2015
)
0.42
"The study was designed to develop a platform to verify whether the extract of herbs combined with chemotherapy drugs play a synergistic role in anti-tumor effects, and to provide experimental evidence and theoretical reference for finding new effective sensitizers."( Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
Chen, Y; Ge, H; Gu, YY; Liao, XZ; Lin, MG; Liu, H; Liu, JH; Liu, TL; Mo, SL; Wang, DM; Xie, J, 2016
)
1.88
" When tanshinone IIA combined with adriamycin at a ratio of 20:1, they exhibited a synergistic anti-proliferation effect on A549 and PC9 cells, but not in HLF cells."( Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
Chen, Y; Ge, H; Gu, YY; Liao, XZ; Lin, MG; Liu, H; Liu, JH; Liu, TL; Mo, SL; Wang, DM; Xie, J, 2016
)
2.36
"Tanshinone IIA can be developed as a novel agent in the postoperative adjuvant therapy combined with other anti-tumor agents, and improve the sensibility of chemotherapeutics for non-small cell lung cancer with fewer side effects."( Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
Chen, Y; Ge, H; Gu, YY; Liao, XZ; Lin, MG; Liu, H; Liu, JH; Liu, TL; Mo, SL; Wang, DM; Xie, J, 2016
)
3.32
" And Tanshinone IIA combined with Taxol was chosen to treat it."( Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau.
Cui, B; Li, S; Lin, H; Lin, Z; Xia, A; Xie, B; Zheng, L; Zhou, P, 2018
)
1.34
" When Tanshinone IIA was combined with cisplatin at a ratio of 20:1, they were observed to exert a synergistic inhibitory effect on non-small-cell lung cancer cells."( Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway.
Chen, HR; Chen, ZZ; Gao, Y; Huang, S; Liao, XZ; Lin, LZ; Liu, JH; Sun, LL; Yu, L; Zhang, JX, 2019
)
2.44
" We also found that DT alone and JF combined with DT inhibited TLR4/PI3K/AKT/mTOR signaling-related proteins expression levels (including TLR4, p-PI3K p110α/PI3K p110α, p-AKT (ser473)/AKT, mTOR, p-mTOR, NF-κB p65), showing an effective anti-inflammatory effect."( Salvia miltiorrhiza stems and leaves total phenolic acids combination with tanshinone protect against DSS-induced ulcerative colitis through inhibiting TLR4/PI3K/AKT/mTOR signaling pathway in mice.
Duan, JA; Gu, JF; Guo, JM; Peng, KY; Qian, DW; Su, SL; Zhu, Y, 2021
)
0.85
"This study aimed to explore the effect of sulfotanshinone sodium injection combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome (ACS)."( Prospective study of the effect of sulfotanshinone sodium combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome.
He, X; Lin, S; Wang, C; Xue, H; Zhai, G, 2021
)
1.15
" Patients treated with sulfotanshinone sodium injection combined with tirofiban (n = 99) were allocated to the research group (RG), and the remaining patients treated with tirofiban alone were allocated to the control group (n = 70; CG)."( Prospective study of the effect of sulfotanshinone sodium combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome.
He, X; Lin, S; Wang, C; Xue, H; Zhai, G, 2021
)
1.18
"Compared with tirofiban alone, sulfotanshinone sodium injection combined with tirofiban had superior efficacy and safety in the treatment of ACS."( Prospective study of the effect of sulfotanshinone sodium combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome.
He, X; Lin, S; Wang, C; Xue, H; Zhai, G, 2021
)
1.16
" However, the effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) are still not fully clear."( Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI.
Liu, X; Lu, Y; Yan, Y, 2021
)
1.15
" The group A was treated with alprostadil, the group B was treated with tanshinone IIa injection, and the group C was treated with alprostadil combined with tanshinone IIa injection."( Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI.
Liu, X; Lu, Y; Yan, Y, 2021
)
1.13
"For AMI patients after PCI, alprostadil combined with tanshinone IIa injection can effectively improve microcirculation and ventricular remodeling, improve cardiac function and reduce the occurrence of MACEs."( Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI.
Liu, X; Lu, Y; Yan, Y, 2021
)
1.14
" Tanshinone IIA (TIIA) combined with cyclosporine A (CsA) pretreatment was used to alleviate myocardial cell apoptosis induced by renal IR, and to determine whether TIIA combined with CsA would attenuate myocardial cell apoptosis by modulating mitochondrial function through the PI3K/Akt/Bad pathway in obese rats."( Tanshinone IIA combined with CsA inhibit myocardial cell apoptosis induced by renal ischemia-reperfusion injury in obese rats.
Jia, LQ; Jiang, XL; Kong, L; Kuang, JS; Lan, ZM; Li, Y; Lv, MJ; Song, N; Tai, H; Wu, J; Xiao, XS; Yang, GL; Yang, P; Yao, SC, 2021
)
2.97
"TIIA combined with CsA can alleviate the pathohistological injury and apoptosis induced by renal IR in myocardial cells."( Tanshinone IIA combined with CsA inhibit myocardial cell apoptosis induced by renal ischemia-reperfusion injury in obese rats.
Jia, LQ; Jiang, XL; Kong, L; Kuang, JS; Lan, ZM; Li, Y; Lv, MJ; Song, N; Tai, H; Wu, J; Xiao, XS; Yang, GL; Yang, P; Yao, SC, 2021
)
2.06
" TIIA combined with CsA attenuated myocardial cell apoptosis by modulating mitochondrial function through the PI3K/Akt/Bad pathway in obese rats."( Tanshinone IIA combined with CsA inhibit myocardial cell apoptosis induced by renal ischemia-reperfusion injury in obese rats.
Jia, LQ; Jiang, XL; Kong, L; Kuang, JS; Lan, ZM; Li, Y; Lv, MJ; Song, N; Tai, H; Wu, J; Xiao, XS; Yang, GL; Yang, P; Yao, SC, 2021
)
2.06
"To systematically evaluate the clinical efficacy and safety of Tanshinone Ⅱ_A Sodium Sulfonate Injection combined with enalapril in the treatment of patients with acute exacerbation of pulmonary heart disease."( [Systematic review and sequential analysis of Tanshinone Ⅱ_A Sodium Sulfonate Injection combined with enalapril in treatment of acute exacerbation of pulmonary heart disease].
Ma, T; Mu, LT; Tian, XT; Yang, J; Zhao, YQ, 2022
)
1.22
"This study aimed to systematically evaluate the efficacy and safety of different Chinese medicine injections combined with conventional western medicine for stable angina pectoris."( [Network Meta-analysis of Chinese medicine injection combined with conventional western medicine in treatment of stable angina pectoris].
Cao, L; Liu, K; Ren, P; Wang, W; Zhu, BB, 2023
)
0.91

Bioavailability

The tanshinones improved the bioavailability of DSS, accelerated the eliminating rate of RA and Sal B and promoted their distribution in vivo. The underlying mechanism of the improvement of oral bioavailability was proposed that coexisting diterpenoids and danxingfang could decrease efflux transport of cryptotanshinone by P-glyco.

ExcerptReferenceRelevance
" The absolute bioavailability of TS was significantly enhanced by oral dicoumarol pretreatment."( Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation.
Cui, N; Ding, Z; Hao, H; Li, J; Wang, G; Xie, L, 2007
)
0.34
" The oral bioavailability of TSB was about 3% in rats with less proportional increase in its maximum plasma concentration (C(max)) and area under the plasma concentration-time curve (AUC) with increasing dosage."( Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of Salvia miltiorrhiza.
Chen, X; Duan, W; Li, XT; Liang, J; Lin, SG; Wen, JY; Yu, XQ; Yu, XY; Zhou, SF; Zhou, ZW, 2007
)
0.57
" Thus bioavailability of tanshinone was improved."( [Preparation of tanshinone microemulsion and its absorption in rat intestine in situ].
Chen, XY; Li, HL; Ma, LL; Zhang, ZY, 2007
)
0.99
" The bioavailability of cryptotanshinone in rats was (6."( Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza).
Bi, HC; Chen, X; Gu, LQ; Huang, M; Huang, ZY; Liu, PQ; Pan, Y; Zhao, LZ; Zhong, GP; Zhou, SF; Zuo, Z, 2008
)
0.85
" However, the low bioavailability of TSNIIA limits its clinical usage."( Tanshinone IIA increases mRNA expression of efflux transporters in cultured human intestinal cell.
Cui, Y; Guan, S; Guo, DA; Jiang, B; Liu, X; Wang, Y; Wu, W; Yang, M; Yin, Y, 2010
)
1.8
"With the increase of dosage of tanshinone II A or cryptotanshinone, K(a) decreased and absorption half life t1/2 increased, the drug absorption rate constant (K(a)) had little significant effect on duodenum, Jejunum and ileum."( [Absorption mechanism of tanshinone II A, cryptotanshinone, tanshinone I and tanshinones extract in rat small intestine in vivo].
Du, S; Li, X; Wu, Q; Yan, H; Yang, Y; Zhou, L, 2010
)
0.95
" They could be well absorbed in general intestinal tract without specific absorption site, and the complex constituents in extract could significant effect the absorption of the pharmaceutical effective constituents."( [Absorption mechanism of tanshinone II A, cryptotanshinone, tanshinone I and tanshinones extract in rat small intestine in vivo].
Du, S; Li, X; Wu, Q; Yan, H; Yang, Y; Zhou, L, 2010
)
0.66
" In conclusion, the addition of poloxamer 188 to pellets containing PVP-based solid dispersions could achieve complete dissolution, accelerated absorption rate and superior oral bioavailability."( Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation.
Fan, YQ; Li, J; Liu, JP; Liu, P; Yang, JK; Zhang, WL, 2012
)
0.86
" The underlying mechanism of the improvement of oral bioavailability was proposed that coexisting diterpenoid tanshinones and danxingfang could decrease the efflux transport of cryptotanshinone by P-glycoprotein."( Coexisted components of Salvia miltiorrhiza enhance intestinal absorption of cryptotanshinone via inhibition of the intestinal P-gp.
Bai, L; Dai, H; Li, X; Li, Y; Xue, M, 2012
)
0.82
" Chemical modifications and novel formulations had been made to address the poor oral bioavailability of tanshinones."( Tanshinones: sources, pharmacokinetics and anti-cancer activities.
Jiang, C; Jiang, P; Kim, SH; Lü, J; Ye, M; Zhang, Y, 2012
)
2.04
"The aim of this study is to improve the dissolution and oral bioavailability of tanshinone IIA (TAN)."( Enhanced dissolution and oral bioavailability of tanshinone IIA base by solid dispersion system with low-molecular-weight chitosan.
Jia, XB; Jiang, YR; Jin, X; Liu, QY; Zhang, ZH, 2013
)
0.87
"In conclusion, the LMC -based solid dispersions could achieve complete dissolution, accelerated absorption rate and superior oral bioavailability."( Enhanced dissolution and oral bioavailability of tanshinone IIA base by solid dispersion system with low-molecular-weight chitosan.
Jia, XB; Jiang, YR; Jin, X; Liu, QY; Zhang, ZH, 2013
)
0.64
" Based on these results, we conclude that the silica nanoparticle based SDs achieved complete dissolution, increased absorption rate, maintained drug stability, and showed improved oral bioavailability compared to TSIIA alone."( Preparation, characterization, and in vivo evaluation of tanshinone IIA solid dispersions with silica nanoparticles.
Chen, XY; Hu, SY; Jia, XB; Jiang, YR; Liu, QY; Zhang, ZH, 2013
)
0.64
" To improve the anti-cancer effect and bioavailability of TAN, we developed a mixed micelle system constituted with D-α-tocopheryl polyethylene glycol succinate-graft-poly(D,L-lactide-co-glycolide) (TPGS-g-PLGA) copolymer and Pluronic F68."( TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy.
Chen, M; Fang, X; Li, Y; Wang, Y; Zhang, J; Zhou, D, 2014
)
0.66
"This study aims to evaluate the oral bioavailability and dissolution of tanshinone IIA (tanIIA) by preparation of solid dispersions (SDs) with porous silica."( Improvement in oral bioavailability and dissolution of tanshinone IIA by preparation of solid dispersions with porous silica.
Cui, L; Jia, XB; Jin, X; Sun, E; Yan, HM, 2015
)
0.9
"SDs with porous silica as carrier could achieve superior oral bioavailability by improving drug dissolution, whereas drug stability could be maintained."( Improvement in oral bioavailability and dissolution of tanshinone IIA by preparation of solid dispersions with porous silica.
Cui, L; Jia, XB; Jin, X; Sun, E; Yan, HM, 2015
)
0.66
" The tanshinones improved the bioavailability of DSS, accelerated the eliminating rate of RA and Sal B and promoted their distribution in vivo."( Simultaneous determination of tanshinones and polyphenolics in rat plasma by UPLC-MS/MS and its application to the pharmacokinetic interaction between them.
Duan, J; Guan, H; Qian, D; Ren, H; Shang, E; Su, S; Zhang, W, 2016
)
1.24
" Cryptotanshinone (CTS), tanshinone I (TSI) and tanshinone IIA (TSA) are the most widely-studied lipophilic ingredients, but low oral bioavailability limits their clinical application."( Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers.
Cheng, JL; Deng, W; Huang, WH; Tan, ZR; Xing, L; Yuan, CS; Zhang, W; Zhou, HH, 2017
)
1.16
"The oral bioavailability and anti-leukaemia activity of Tanshinone IIA (TanIIA) were enhanced by using biotinylated-lipid bilayer coated mesoporous silica nanoparticles (Bio-LB-MSNs) as a vehicle."( Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA.
Feng, N; Li, Z; Wu, Z; Zhang, K; Zhang, Y, 2018
)
0.93
" All of the analytes displayed significant higher area under the concentration-time curve and peak concentration after oral administration of UGP than after TDS, indicating that ultrafine powder product could improve the bioavailability and absorption of cryptotanshinon,tanshinone II A,dihydrotanshinonE I and tanshinone I in vivo."( Comparative in vivo constituents and pharmacokinetic study in rats after oral administration of ultrafine granular powder and traditional decoction slices of Chinese Salvia.
Cheng, J; Deng, W; Deng, Y; Guo, D; Hou, J; Li, Z; Qi, P; Wu, W; Zhi, H, 2019
)
0.69
" However, the intrinsically poor solubility and bioavailability of tanshinone IIA hindered its clinical application."( Nanoparticle-mediated delivery of Tanshinone IIA reduces adverse cardiac remodeling following myocardial infarctions in a mice model: role of NF-κB pathway.
Chen, P; Guo, R; Lan, Y; Mao, S; Wang, L; Zhang, M, 2018
)
1
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, although these products have demonstrated important biological properties in both in vitro and in vivo models, their poor solubility and bioavailability have limited their clinical applications."( Tanshinones and their Derivatives: Heterocyclic Ring-Fused Diterpenes of Biological Interest.
Alonso, MM; Córdova-Guerrero, I; Díaz-Rubio, L; Estolano-Cobián, A; Marrero, JG; Ponce, CN, 2021
)
2.06
" However, it suffers from poor oral bioavailability owing to low aqueous solubility, poor permeability and exposure to first-pass metabolism."( Enhanced oral bioavailability of Tanshinone IIA using lipid nanocapsules: Formulation, in-vitro appraisal and pharmacokinetics.
Abdelmonsif, DA; Ashour, AA; El-Kamel, AH; Ramadan, AA, 2020
)
0.84
" However, the poor water solubility and low oral bioavailability of TA limited its clinical application."( Preparation of water-soluble chitosan/poly-gama-glutamic acid-tanshinone IIA encapsulation composite and its in vitro/in vivo drug release properties.
Wu, N; Yu, J; Zheng, M; Zheng, X, 2020
)
0.8
"BO-TA-Lip had higher bioavailability and better absorption in brain tissue, and could improve cerebral ischemia reperfusion injury, which might be related to the inhibitory effect of BO-TA-Lip in expression of NF-κB and ICAM-1."( Borneol-modified tanshinone IIA liposome improves cerebral ischemia reperfusion injury by suppressing NF-κB and ICAM-1 expression.
Cai, X; Huang, Y; Peng, X; Song, Q; Wang, B; Wang, C; Xiong, X; Ye, X; Zeng, T; Zhang, C, 2021
)
0.96
" Therefore, this work aimed at enhancing TSIIA systemic bioavailability together with achieving active targeting potential to fibrotic liver via its incorporation into novel modified lipid nanocapsules (LNCs)."( Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis.
Abdelmonsif, DA; Ashour, AA; El-Kamel, AH; Khalifa, HM; Ramadan, AA, 2021
)
0.89
" The oral bioavailability of EMO and Tan IIA was significantly improved when they were loaded into the hierarchically structured microcapsules, ultimately contributing to superior therapeutic outcomes in rats with unilateral ureteral obstruction."( Hierarchically structured microcapsules for oral delivery of emodin and tanshinone IIA to treat renal fibrosis.
Fan, X; Hou, Y; Li, F; Piao, J; Sun, J; Wei, Y; Xu, Z; Yao, W; Zheng, H, 2022
)
0.95
"The encapsulation of three drug components in the emulsion can improve the oral bioavailability to varying degrees and can effectively prevent the acute liver injury caused by acetaminophen."( [Preparation of salvianolic acid B, tanshinone Ⅱ_A, and glycyrrhetinic acid lipid emulsion and its protective effect against acute liver injury induced by acetaminophen].
Gu, H; Lin, T; Wang, XJ; Wang, XL; Zhang, XR, 2022
)
1

Dosage Studied

Tanshinone IIA can decrease the overexpression of AQP5 induced by seawater. A reduction in the cytotoxicity of irinotecan is observed following dosing with either purified tanshinones or S.

ExcerptRelevanceReference
" The effects do not increase with the dosage escalation of ATRA."( [Differentiation and apoptosis of NB4 cells synergistically induced by Tanshinone II A and all-trans retinoic acid].
Huang, CL; Liu, ZG; Meng, WT; Yang, YM, 2004
)
0.56
" With the increase of dosage of complex, its absorption did not show saturated phenomenon in gastro-intestinal tract in rats and the constant Ka did not show significant difference, suggesting that the transport of mechanism in vivo is similar to passive transport."( [Studies on absorptive mechanism of lipophilic components of danshen from its hydroxypropyl-beta-cyclodextrin inclusion complex].
Jiang, X; Wang, L; Yang, J; Zhou, J, 2006
)
0.33
" The patient was administered with all-trans retinoic acid (ATRA) with dosage of 20 mg three times per day."( [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A].
Liu, T; Yang, YM, 2006
)
0.55
"4% in rats, with non-linear pharmacokinetics when its dosage increased."( Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Chen, X; Chowbay, B; Duan, W; Li, CG; Liang, J; Lin, SG; Liu, PQ; Wen, JY; Yu, XY; Zhou, SF; Zhou, ZW, 2007
)
0.59
" With the increase of dosage of complex, TS IIA's absorption did not show saturated phenomenon, suggesting its transport mechanism in vivo might primary be passive transport."( In situ intestinal absorption behaviors of tanshinone IIA from its inclusion complex with hydroxypropyl-beta-cyclodextrin.
Hua, JX; Ling, W; Rui, LC, 2007
)
0.6
" The dosage given to the low dose groups was half that of the medium dose groups, while the high dose groups received twice the dosage of the medium dose groups."( Pharmacokinetic interaction between tanshinones and polyphenolic extracts of salvia miltinorrhiza BUNGE after intravenous administration in rats.
Guo, ZJ; Li, H; Sun, QS; Tang, X; Zhang, Y, 2008
)
0.62
" This synergistic effects is related to the dosage and treatment time."( [Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Meng, WT; Yang, YM; Zhang, G; Zhou, J, 2010
)
0.64
"The experimental results showed that tanshinone IIA is innocuous to A549 at a dosage of 25 μg/ml, and it can decrease the overexpression of AQP5 induced by seawater."( [Effect of sulfonic tanshinone sodium injection on the expression and activity of aquaporin-5 of human alveolar epithelial cells after seawater exposure].
Fan, QX; Jin, FG; Li, JH; Li, ZC; Xie, XY; Xu, M; Zhang, B; Zhang, Y; Zhao, PT, 2011
)
0.97
"With the increase of dosage of tanshinone II A or cryptotanshinone, K(a) decreased and absorption half life t1/2 increased, the drug absorption rate constant (K(a)) had little significant effect on duodenum, Jejunum and ileum."( [Absorption mechanism of tanshinone II A, cryptotanshinone, tanshinone I and tanshinones extract in rat small intestine in vivo].
Du, S; Li, X; Wu, Q; Yan, H; Yang, Y; Zhou, L, 2010
)
0.95
" Overall, the Tan IIA-LE developed in this study was suggested to be a suitable and safe dosage form of Tan IIA for intravenous administration and has potential in liver cancer therapy in future."( Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity in vitro.
Chu, T; Jin, H; Li, H; Ma, WC; Mao, SJ; Zhang, N; Zhang, Q, 2012
)
0.64
" The 25 mg/kg dosage was more effective."( Neuroprotective capabilities of Tanshinone IIA against cerebral ischemia/reperfusion injury via anti-apoptotic pathway in rats.
Chen, Y; Fauzee, NJ; Li, L; Wu, J; Wu, X; Yu, S; Zhao, J; Zhao, Y, 2012
)
0.66
"The preparation of tanshinone IIA micro- emulsion is simple,corresponding to the main index of parenteral injection and offering the basis for new dosage form development of tanshinone IIA."( [Preparation and quality evaluation of tanshinone IIA microemulsion for parenteral injection].
Deng, XL; He, L; Long, XY; Lu, XX; Xu, YJ, 2014
)
1
" Several liquisolid tablets (LS) formulations containing different dosage of drugs and various liquid vehicle were pre-pared and for all the formulations, microcrystalline cellulose and silica were chosen as the carrier and coating materials to evaluate their flow properties, such as angle of repose, Carr's compressibility index and Hausner's ratio."( [Liquisolid technique for enhancement of dissolution prosperities of tanshinone II(A)].
Liu, XQ; Meng, QJ; Xu, XL; Yang, H; Yi, H; Zhao, J, 2015
)
0.65
" This design could reduce the dosage of AgNPs while maintaining antibacterial activity possibly due to the favorable interactions between nanocomplex and bacteria."( A Tanshinone IIA loaded hybrid nanocomposite with enhanced therapeutic effect for otitis media.
Chen, G; Chen, X; Hu, H; Liang, Y; Wen, L; Yu, H; Zeng, P, 2020
)
1.28
" This may be related to factors such as the population and the dosage and time of taking natural products involved in different studies."( Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis.
Chen, W; Feng, X; Li, L; Xu, S; Zhang, L; Zhang, S, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
abietane diterpenoidA diterpenoid based on an abietane skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (60)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency11.22020.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency1.25590.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency35.48130.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency10.69100.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency39.81070.100020.879379.4328AID588453
BRCA1Homo sapiens (human)Potency3.16230.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency3.76010.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency8.06030.180013.557439.8107AID1460; AID1468
thioredoxin glutathione reductaseSchistosoma mansoniPotency8.91250.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency12.58930.707912.194339.8107AID720542
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.34500.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency11.77040.001310.157742.8575AID1259253
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.41250.28189.721235.4813AID2326
GVesicular stomatitis virusPotency9.52210.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency3.37860.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency4.94900.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
P53Homo sapiens (human)Potency2.51190.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.16230.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency63.09570.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency15.84890.006026.168889.1251AID540317
DNA polymerase betaHomo sapiens (human)Potency19.95260.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency10.00000.133725.412989.1251AID588795
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency28.18380.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency6.30960.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency9.08440.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency79.43280.031622.3146100.0000AID588579
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency79.43286.309660.2008112.2020AID720709
Glycoprotein hormones alpha chainHomo sapiens (human)Potency5.01194.46688.344810.0000AID624291
Interferon betaHomo sapiens (human)Potency9.52210.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency9.52210.01238.964839.8107AID1645842
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.62341.995325.532750.1187AID624287
TAR DNA-binding protein 43Homo sapiens (human)Potency6.30961.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency9.52210.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency9.52210.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAD51Homo sapiens (human)IC50 (µMol)85.00001.399017.721432.1000AID1436
Cocaine esteraseHomo sapiens (human)Ki7.98000.00630.98358.0000AID731513; AID731514
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)16.45000.00312.16029.6000AID1845959; AID1872430
Polycomb protein EEDHomo sapiens (human)IC50 (µMol)8.90000.00201.21958.9000AID1151968
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)14.92500.03002.29719.5100AID688188; AID688189; AID688191; AID688308
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusKi13.70000.00753.23929.1100AID688190
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)38.70000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusKi13.70000.00753.00839.1100AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)20.45500.00022.45859.9600AID1805801; AID1884031
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2Ki13.70000.00001.63079.0000AID1805801
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)50.00000.00000.933210.0000AID1056365
AcetylcholinesteraseHomo sapiens (human)Ki100.00000.00001.27869.7300AID731511; AID731512
Liver carboxylesterase 1Homo sapiens (human)Ki26.25000.00252.01368.4800AID731515
Tyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)IC50 (µMol)1.97000.29002.20754.2300AID772620
Tyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)IC50 (µMol)2.57000.31804.00429.6000AID772622
Polycomb protein SUZ12Homo sapiens (human)IC50 (µMol)8.90000.00401.61908.9000AID1151968
Histone-lysine N-methyltransferase EZH2Homo sapiens (human)IC50 (µMol)8.90000.00030.50478.9000AID1151968
Hypoxia-inducible factor 1-alphaHomo sapiens (human)IC50 (µMol)10.50500.00072.46529.2100AID291914; AID291915
Endothelial PAS domain-containing protein 1Homo sapiens (human)IC50 (µMol)10.50500.00302.60028.5100AID291914; AID291915
Protease Human immunodeficiency virus 1IC50 (µMol)45.90000.00000.81769.8500AID688197
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)76.37650.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (369)

Processvia Protein(s)Taxonomy
prostaglandin metabolic processCocaine esteraseHomo sapiens (human)
xenobiotic metabolic processCocaine esteraseHomo sapiens (human)
catabolic processCocaine esteraseHomo sapiens (human)
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
spinal cord developmentPolycomb protein EEDHomo sapiens (human)
negative regulation of DNA-templated transcriptionPolycomb protein EEDHomo sapiens (human)
heterochromatin formationPolycomb protein EEDHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolycomb protein EEDHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of humoral immune response mediated by circulating immunoglobulinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
natural killer cell mediated cytotoxicityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of apoptotic processTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of B cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet aggregationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of inflammatory response to woundingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
epididymis developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
intracellular signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
triglyceride metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
axonogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
brain developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
heart developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cerebellar cortex formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of chondrocyte differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
microvillus organizationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interferon-beta productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organism growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
organ growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
atrioventricular canal developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein-containing complex assemblyTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ossificationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of glucose importTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of insulin secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein export from nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organismal reproductive processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
genitalia developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
inner ear developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
homeostasis of number of cells within a tissueTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cortisol secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of growth hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
face morphogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
intestinal epithelial cell migrationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolycomb protein SUZ12Homo sapiens (human)
cell population proliferationPolycomb protein SUZ12Homo sapiens (human)
positive regulation of cell population proliferationPolycomb protein SUZ12Homo sapiens (human)
negative regulation of cell differentiationPolycomb protein SUZ12Homo sapiens (human)
oligodendrocyte differentiationPolycomb protein SUZ12Homo sapiens (human)
random inactivation of X chromosomePolycomb protein SUZ12Homo sapiens (human)
facultative heterochromatin formationPolycomb protein SUZ12Homo sapiens (human)
G1/S transition of mitotic cell cycleHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of cell population proliferationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of gliogenesisHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
skeletal muscle satellite cell maintenance involved in skeletal muscle regenerationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cerebellar cortex developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
hippocampus developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
B cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
keratinocyte differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of cell migrationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulatory ncRNA-mediated heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
subtelomeric heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
methylationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
response to estradiolHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cellular response to trichostatin AHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein modification processHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
hepatocyte homeostasisHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of circadian rhythmHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of MAP kinase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of GTPase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of keratinocyte differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of retinoic acid receptor signaling pathwayHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
rhythmic processHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
stem cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of striated muscle cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
synaptic transmission, GABAergicHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
cellular response to hydrogen peroxideHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
G1 to G0 transitionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein localization to chromatinHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
regulation of kidney developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
liver regenerationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
facultative heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of dendrite developmentHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of cell cycle G1/S phase transitionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
response to tetrachloromethaneHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
negative regulation of stem cell differentiationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
heterochromatin formationHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
angiogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
embryonic placenta developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
blood vessel remodelingEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of heart rateEndothelial PAS domain-containing protein 1Homo sapiens (human)
epithelial cell maturationEndothelial PAS domain-containing protein 1Homo sapiens (human)
response to oxidative stressEndothelial PAS domain-containing protein 1Homo sapiens (human)
mitochondrion organizationEndothelial PAS domain-containing protein 1Homo sapiens (human)
signal transductionEndothelial PAS domain-containing protein 1Homo sapiens (human)
visual perceptionEndothelial PAS domain-containing protein 1Homo sapiens (human)
erythrocyte differentiationEndothelial PAS domain-containing protein 1Homo sapiens (human)
lung developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
norepinephrine metabolic processEndothelial PAS domain-containing protein 1Homo sapiens (human)
mRNA transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
surfactant homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
myoblast fate commitmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
cellular response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of cold-induced thermogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of protein neddylationEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (128)

Processvia Protein(s)Taxonomy
methylumbelliferyl-acetate deacetylase activityCocaine esteraseHomo sapiens (human)
carboxylesterase activityCocaine esteraseHomo sapiens (human)
carboxylic ester hydrolase activityCocaine esteraseHomo sapiens (human)
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription corepressor bindingPolycomb protein EEDHomo sapiens (human)
protein bindingPolycomb protein EEDHomo sapiens (human)
enzyme activator activityPolycomb protein EEDHomo sapiens (human)
histone methyltransferase activityPolycomb protein EEDHomo sapiens (human)
identical protein bindingPolycomb protein EEDHomo sapiens (human)
nucleosome bindingPolycomb protein EEDHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH2 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
signaling receptor complex adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
molecular adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPolycomb protein SUZ12Homo sapiens (human)
transcription corepressor bindingPolycomb protein SUZ12Homo sapiens (human)
protein bindingPolycomb protein SUZ12Homo sapiens (human)
enzyme activator activityPolycomb protein SUZ12Homo sapiens (human)
methylated histone bindingPolycomb protein SUZ12Homo sapiens (human)
histone methyltransferase activityPolycomb protein SUZ12Homo sapiens (human)
metal ion bindingPolycomb protein SUZ12Homo sapiens (human)
lncRNA bindingPolycomb protein SUZ12Homo sapiens (human)
promoter-specific chromatin bindingPolycomb protein SUZ12Homo sapiens (human)
chromatin DNA bindingPolycomb protein SUZ12Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
transcription corepressor activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin DNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
ribonucleoprotein complex bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
primary miRNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
lncRNA bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
histone H3K27 trimethyltransferase activityHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription coactivator bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein heterodimerization activityEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (69)

Processvia Protein(s)Taxonomy
endoplasmic reticulumCocaine esteraseHomo sapiens (human)
endoplasmic reticulum lumenCocaine esteraseHomo sapiens (human)
intracellular membrane-bounded organelleCocaine esteraseHomo sapiens (human)
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusPolycomb protein EEDHomo sapiens (human)
nucleoplasmPolycomb protein EEDHomo sapiens (human)
chromosomePolycomb protein EEDHomo sapiens (human)
cytosolPolycomb protein EEDHomo sapiens (human)
ESC/E(Z) complexPolycomb protein EEDHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular regionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleolusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell-cell junctionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
specific granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular exosomeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
tertiary granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
alpha-beta T cell receptor complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusPolycomb protein SUZ12Homo sapiens (human)
nucleoplasmPolycomb protein SUZ12Homo sapiens (human)
nucleolusPolycomb protein SUZ12Homo sapiens (human)
nuclear bodyPolycomb protein SUZ12Homo sapiens (human)
sex chromatinPolycomb protein SUZ12Homo sapiens (human)
chromatin silencing complexPolycomb protein SUZ12Homo sapiens (human)
ESC/E(Z) complexPolycomb protein SUZ12Homo sapiens (human)
ribonucleoprotein complexPolycomb protein SUZ12Homo sapiens (human)
RSC-type complexPolycomb protein SUZ12Homo sapiens (human)
nucleusPolycomb protein SUZ12Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromosome, telomeric regionHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
pronucleusHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
synapseHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
chromatin silencing complexHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
pericentric heterochromatinHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
ESC/E(Z) complexHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EZH2Homo sapiens (human)
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmEndothelial PAS domain-containing protein 1Homo sapiens (human)
cytosolEndothelial PAS domain-containing protein 1Homo sapiens (human)
nuclear speckEndothelial PAS domain-containing protein 1Homo sapiens (human)
chromatinEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription regulator complexEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (128)

Assay IDTitleYearJournalArticle
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID291916Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID1733467Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 2.5 uM after 24 hrs by annexin V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 1.22%)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID246853Dose required for reduction in cell growth of human breast cancer MCF-7 cell line2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza.
AID731516Reduction of CPT-11 sensitization to human U373MG cells expressing human iCE treated 1 hr before CPT-11 challenge measured after 72 hrs relative to DMSO control2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID731510Inhibition of human iCE in human U373MG cells assessed as 4-MUA substrate hydrolysis at 1 uM after 1 hr by fluorescence spectrometry assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID1733477Induction of apoptosis in human MCF7 cells assessed as increase in cell death at 2.5 uM after 24 hrs by EtBr/AO staining based fluorescence microscopic method2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID1455094Induction of apoptosis in human HCT116 cells pretreated with Z-VAD-FMK pan-caspase inhibitor for 1 hr assessed as activation of caspase 3/7 at 1.0 to 4.0 uM after 24 hrs by Western blot analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455076Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 2.35%)2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID731513Inhibition of human iCE using CPT-11 as substrate by spectrophotometric assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID481927Induction of apoptosis in human Hep3B cells deficient in p53 gene assessed as PARP cleavage by Western blot2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID772622Inhibition of GST-tagged SHP2 PTP domain (unknown origin) using phospho-EGFR Asp-Ala-Asp-Glu-Tyr[PO3H2]-Leu-Ile-Pro-Gln-Gln-Gly as substrate preincubated for 30 mins before substrate addition measured after 30 mins by phosphatase activity assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
AID481928Induction of apoptosis in human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) assessed as PARP cleavage by Western blot2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1733470Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 2.5 uM after 24 hrs by annexin V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 0.65%)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID731514Inhibition of human iCE using o-NPA as substrate by spectrophotometric assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID1733463Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID1151968Inhibition of EZH2 histone methyltransferase activity in EZH2/SUZ12/EED protein complex (unknown origin) using histone H3 peptide/S-adenosylmethionine as substrate after 2 hrs by TR-FRET assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1733464Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID481923Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID246871Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza.
AID688311Non competitive inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by Dixon plot analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID688190Time dependent inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate at 3 to 100 uM up to 120 mins2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID688310Non competitive inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate by Dixon plot analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1455077Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 5.74%)2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1733465Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 2.5 uM after 24 hrs by annexin V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 3.94%)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID688195Inhibition of papaya papain using N-alpha-benzoyl-L-arginine-pnitroanilide as substrate at 200 uM after 5 mins2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1873256Anti-obesity activity in male C57BL/6 mouse model of high-fat diet induced obesity assessed as body weight change at 5 mg/kg, po administered thrice a week for 8 weeks relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
AID1455048Half life in mouse liver microsomes at 0.1 uM up to 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID291918Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID1455049Intrinsic clearance in human liver microsomes assessed as per mg protein up to 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455043Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID291914Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID731515Inhibition of human CE1 using o-NPA as substrate by spectrophotometric assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID1455051Intrinsic clearance in mouse liver microsomes assessed per mg protein up to 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455044Antiproliferative activity against human KB/VCR cells after 72 hrs by sulforhodamine B assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455041Half life in Sprague-Dawley rat at 3.90 mg/kg, po by LC-ESI-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455082Induction of apoptosis in human HCT116 cells pretreated with Z-VAD-FMK pan-caspase inhibitor for 1 hr assessed as early apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 1.34%)2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID481929Induction of apoptosis in human HepG2 cells expressing wild type p53 gene assessed as caspase 3 activation2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID731511Inhibition of human BChE using butyrylthiocholine as substrate by spectrophotometric assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID688197Inhibition of Human immunodeficiency virus 1 protease preincubated for 10 mins by FRET assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1455042Oral bioavailability in Sprague-Dawley rat at 3.90 mg/kg by LC-ESI-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID481926Induction of apoptosis in human HepG2 cells expressing wild type p53 gene assessed as PARP cleavage by Western blot2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID612372Cytotoxicity against human MV-3 cells after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica.
AID291915Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
AID1872430Inhibition of KDM1A (unknown origin) by fluorescence based assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID688193Inhibition of chymotrypsin using N-benzoyl-L-tyrosine ethyl ester as substrate assessed as benzoyl-tyrosine production measured every 10 seconds for 6 mins2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID688305Time dependent inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate at 1 to 100 uM by FRET analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1455093Induction of apoptosis in human HCT116 cells assessed as activation of caspase 3/7 at 1.0 to 4.0 uM after 24 hrs by Western blot analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID688306Time dependent inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate at IC50 by fluorescence assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1455050Intrinsic clearance in rat liver microsomes assessed per mg protein up to 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455092Induction of apoptosis in human HCT116 cells pretreated with Z-VAD-FMK pan-caspase inhibitor for 1 hr assessed as cleavage of PARP at 2 uM after 48 hrs by Western blot analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1845959Inhibition of LSD1 (unknown origin) by Spectra Max Paradigm Microplate Reader analysis2021European journal of medicinal chemistry, Mar-15, Volume: 214Annual review of LSD1/KDM1A inhibitors in 2020.
AID1884031Inhibition of full-length SARS-CoV-2 papain-like protease (1564 to 1878 residues) expressed in Escherichia coli Rosetta (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by multimode plate reader analysis2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID688188Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 30 mins by fluorescence assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID481940Inhibition of P-gp in doxorubicin-resistant human HepG2 cells assessed as potentiation of doxorubicin cytostatic effect at 6.25 uM by MTT assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1733469Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 2.5 uM after 24 hrs by annexin V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 0.08%)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID1733478Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cell death at 2.5 uM after 24 hrs by EtBr/AO staining based fluorescence microscopic method2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID688189Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1455047Half life in rat liver microsomes at 0.1 uM up to 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID481931Induction of apoptosis in human Hep3B cells deficient in p53 gene assessed as caspase 3 activation2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1455083Induction of apoptosis in human HCT116 cells pretreated with Z-VAD-FMK pan-caspase inhibitor for 1 hr assessed as late apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 3.15%)2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID612371Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica.
AID481925Cytotoxicity against human THLE3 cells by MTT assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID772620Inhibition of GST-tagged SHP1 PTP domain (unknown origin) using phospho-EGFR Asp-Ala-Asp-Glu-Tyr[PO3H2]-Leu-Ile-Pro-Gln-Gln-Gly as substrate preincubated for 30 mins before substrate addition measured after 30 mins by phosphatase activity assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
AID1455046Half life in human liver microsomes at 0.1 uM up to 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID481934Effect on MRP1 protein expression in human HepG2 cells expressing wild type p53 gene at 25 uM after 24 hrs by Western blot2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1455040Aqueous solubility of the compound by HPLC method2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID481922Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1455090Induction of apoptosis in human HCT116 cells assessed as activation of caspase 3/7 at 2 uM after 48 hrs by Western blot analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID688191Inhibition of SARS-CoV PLpro deubiququitination expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1733526Induction of autophagy in human MCF7 cells assessed as LC3-2 to LC3-1 protein ratio at 2.5 uM after 24 hrs by Western blot analysis (Rvb = 0.22 to 0.8 No_unit)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID1733468Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 2.5 uM after 24 hrs by annexin V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 1.54%)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID481924Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID481935Effect on MRP2 protein expression in human HepG2 cells expressing wild type p53 gene at 25 uM after 24 hrs by Western blot2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1455089Induction of apoptosis in human HCT116 cells assessed as cleavage of PARP at 2 uM after 48 hrs by Western blot analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1455091Induction of apoptosis in human HCT116 cells pretreated with Z-VAD-FMK pan-caspase inhibitor for 1 hr assessed as activation of caspase 3/7 at 2 uM after 48 hrs by Western blot analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID731512Inhibition of human AChE using acetylthiocholine as substrate by spectrophotometric assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
AID481921Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID1056365Inhibition of acetylcholinesterase (unknown origin)2013ACS medicinal chemistry letters, Nov-14, Volume: 4, Issue:11
Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility.
AID1733466Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 2.5 uM after 24 hrs by annexin V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 0.2%)2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Identification of two novel thiophene analogues as inducers of autophagy mediated cell death in breast cancer cells.
AID688307Inhibition of SARS-CoV PLpro expressed in Escherichia coli (DE3) BL21 using Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 60 mins by fluorescence assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID688308Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
AID1884032Antiviral activity against SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells assessed as viral growth inhibition pretreated for 1 hr followed by infection at MOI of 0.01 and replacement of fresh medium containing 2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1884033Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID694263Inhibition of human recombinant telomerase activity in rabbit reticulocytes at 50 uM after 90 mins by telomerase assemblage gel electrophoresis2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
ortho-Quinone tanshinones directly inhibit telomerase through an oxidative mechanism mediated by hydrogen peroxide.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,425)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (1.19)18.7374
1990's28 (1.96)18.2507
2000's281 (19.72)29.6817
2010's785 (55.09)24.3611
2020's314 (22.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.85 (24.57)
Research Supply Index7.28 (2.92)
Research Growth Index5.64 (4.65)
Search Engine Demand Index60.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (0.69%)5.53%
Reviews64 (4.43%)6.00%
Case Studies2 (0.14%)4.05%
Observational0 (0.00%)0.25%
Other1,369 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention [NCT02524964]Phase 460 participants (Anticipated)Interventional2015-12-31Recruiting
Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension [NCT01637675]Phase 2/Phase 390 participants (Anticipated)Interventional2013-05-31Recruiting
Effect of Tanshinone on Hormonal and Metabolic Features in Women With Polycystic Ovary Syndrome (PCOS) [NCT01452477]100 participants (Anticipated)Interventional2011-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]